View Filing Data

Weighted-Average
Grant-Date
Fair Value

Share options

Restricted share units

Print Document View Excel Document

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Jun. 28, 2013	Jul. 31, 2013
Entity Information [Line Items]
Entity Registrant Name	Mallinckrodt plc
Entity Central Index Key	0001567892
Trading Symbol	MNK
Current Fiscal Year End Date	--09-27
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 28, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Amendment Flag	false
Ordinary Shares Outstanding		57,697,184

Consolidated Combined Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Jun. 28, 2013	Jun. 29, 2012	Jun. 28, 2013	Jun. 29, 2012
Income Statement [Abstract]
Net sales	$ 570.0	$ 516.3	$ 1,659.3	$ 1,543.1
Cost of sales	304.2	273.1	886.5	811.6
Gross profit	265.8	243.2	772.8	731.5
Selling, general and administrative expenses	166.9	137.2	474.4	411.3
Research and development expenses	44.8	35.2	122.4	107.5
Separation costs	44.2	7.2	70.6	17.4
Restructuring charges, net	11.3	5.0	17.9	10.5
Gain on divestiture	(0.8)	(0.8)	(2.2)	(2.2)
Operating income (loss)	(0.6)	59.4	89.7	187.0
Interest expense	(9.4)	(0.1)	(9.6)	(0.4)
Interest income	0.0	0.1	0.1	0.4
Other income, net	2.1	0.1	2.3	0.8
Income (loss) from continuing operations before income taxes	(7.9)	59.5	82.5	187.8
Provision for income taxes	19.8	24.4	55.9	73.8
Income (loss) from continuing operations	(27.7)	35.1	26.6	114.0
Loss from discontinued operations, net of income taxes	(0.2)	(1.9)	(1.3)	(5.6)
Net income (loss)	$ (27.9)	$ 33.2	$ 25.3	$ 108.4
Basic earnings per share:
Income (loss) from continuing operations (in usd per share)	$ (0.48)	$ 0.61	$ 0.46	$ 1.98
Loss from discontinued operations (in usd per share)	0.00	(0.03)	(0.02)	(0.10)
Net income (loss) (in usd per share)	(0.48)	0.58	0.44	1.88
Diluted earnings per share:
Income (loss) from continuing operations (in usd per share)	(0.48)	0.61	0.46	1.98
Loss from discontinued operations (in usd per share)	0.00	(0.03)	(0.02)	(0.10)
Net income (loss) (in usd per share)	$ (0.48)	$ 0.58	$ 0.44	$ 1.88
Weighted-average number of shares outstanding:
Basic (in shares)	57.7	57.7	57.7	57.7
Diluted (in shares)	57.7	57.7	57.7	57.7

Consolidated Combined Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 28, 2013	Jun. 29, 2012	Jun. 28, 2013	Jun. 29, 2012
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (27.9)	$ 33.2	$ 25.3	$ 108.4
Other comprehensive income (loss), net of tax
Currency translation adjustments	(6.6)	(11.1)	(14.8)	(11.3)
Unrecognized loss on derivatives	(3.4)	0.0	(7.4)	0.0
Unrecognized gain (loss) on benefit plans	3.6	2.8	1.9	(1.6)
Total other comprehensive loss, net of tax	(6.4)	(8.3)	(20.3)	(12.9)
Comprehensive income (loss)	$ (34.3)	$ 24.9	$ 5.0	$ 95.5

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Condensed Consolidated and Combined Balance Sheets - USD ($) $ in Millions	Jun. 28, 2013	Sep. 28, 2012
Current Assets:
Cash and cash equivalents	$ 180.4	$ 0.0
Accounts receivable, less allowance for doubtful accounts of $4.5 and $9.4	324.3	291.1
Inventories	423.1	435.3
Deferred income taxes	140.6	119.9
Prepaid expenses and other current assets	78.7	31.0
Total current assets	1,147.1	877.3
Property, plant and equipment, net	977.9	945.2
Goodwill	532.0	507.5
Intangible assets, net	430.9	365.6
Other assets	224.3	179.0
Total Assets	3,312.2	2,874.6
Current Liabilities:
Current maturities of long-term debt	1.4	1.3
Accounts payable	99.1	112.5
Accrued and other current liabilities	381.3	282.0
Total current liabilities	481.8	395.8
Long-term debt	918.5	8.9
Pension and postretirement benefits	161.6	189.6
Environmental liabilities	39.2	136.5
Deferred income taxes	241.1	73.7
Other income tax liabilities	140.7	19.4
Other liabilities	171.3	158.8
Total Liabilities	2,154.2	982.7
Commitments and contingencies (note 13)
Shareholders' Equity:
Preferred shares, $0.20 par value, 500,000,000 authorized; none issued and outstanding	0.0	0.0
Ordinary shares, $0.20 par value, 500,000,000 authorized; 57,694,885 issued and outstanding	11.5	0.0
Contributed surplus	1,086.7	0.0
Parent company investment	0.0	1,807.0
Accumulated other comprehensive income	59.8	84.9
Total Shareholders' Equity	1,158.0	1,891.9
Total Liabilities and Shareholders' Equity	$ 3,312.2	$ 2,874.6

Condensed Consolidated and Combined Balance Sheets (Parenthetical) - USD ($) $ in Millions	Jun. 28, 2013	Sep. 28, 2012
Statement of Financial Position [Abstract]
Accounts receivable trade, allowance for doubtful accounts	$ 4.5	$ 9.4
Ordinary shares, par value (in usd per share)	$ 0.20	$ 0
Ordinary shares, authorized (in shares)	500,000,000	0
Ordinary shares, issued (in shares)	57,694,885	0
Ordinary stock, outstanding (in shares)	57,694,885
Preferred shares, par value (in usd per share)	$ 0.20	$ 0
Preferred shares, authorized (in shares)	500,000,000	0
Preferred shares, issued (in shares)	0	0

Condensed Combined Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Jun. 28, 2013	Jun. 29, 2012
Cash Flows From Operating Activities:
Net income	$ 25.3	$ 108.4
Loss from discontinued operations, net of income taxes	1.3	5.6
Income from continuing operations	26.6	114.0
Adjustments to reconcile net cash provided by operating activities:
Depreciation and amortization	102.2	97.4
Share-based compensation	11.4	8.3
Deferred income taxes	7.5	6.7
Other non-cash items	(4.3)	(6.0)
Changes in assets and liabilities, net of the effects of acquisitions:
Accounts receivable, net	(131.8)	31.8
Inventories	12.3	(53.6)
Accounts payable	(8.9)	(7.9)
Income taxes	39.8	60.5
Accrued and other liabilities	(30.9)	(55.5)
Other	(17.7)	8.5
Net cash provided by operating activities	6.2	204.2
Cash Flows From Investing Activities:
Capital expenditures	(110.5)	(102.3)
Acquisition, net of cash acquired	(88.1)	0.0
Other	0.1	0.7
Net cash (used in) investing activities	(198.5)	(101.6)
Cash Flows From Financing Activities:
Issuance of external debt	898.1	0.0
Repayment of capital leases	(1.0)	(1.0)
Debt financing costs	(12.0)	0.0
Excess tax benefit from share-based compensation	3.4	2.0
Net transfers to parent	(515.9)	(103.6)
Other	0.1	0.0
Net cash provided by (used in) financing activities	372.7	(102.6)
Effect of currency rate changes on cash	0.0	0.0
Net increase in cash and cash equivalents	180.4	0.0
Cash and cash equivalents at beginning of period	0.0	0.0
Cash and cash equivalents at end of period	$ 180.4	$ 0.0

Condensed Consolidated and Combined Statement of Changes in Shareholders' Equity Statement - 9 months ended Jun. 28, 2013 - USD ($) $ in Millions	Total	Ordinary Shares	Contributed Surplus	Parent Company Investment	Accumulated Other Comprehensive Income
Beginning balance, shares at Sep. 28, 2012		0
Beginning balance at Sep. 28, 2012	$ 1,891.9	$ 0.0	$ 0.0	$ 1,807.0	$ 84.9
Net income	25.3			25.3
Currency translation adjustments	(14.8)				(14.8)
Change in derivatives, net of tax	(7.4)				(7.4)
Minimum pension liability, net of tax	1.9				1.9
Net transfers to parent	(515.9)			(515.9)
Separation related adjustments	$ (223.0)			(218.2)	(4.8)
Transfer of parent company investment to contributed surplus			1,098.2	(1,098.2)
Issuance of ordinary shares, shares		57,700,000
Issuance of ordinary shares, value		$ 11.5	(11.5)
Ending balance, shares at Jun. 28, 2013	57,694,885	57,700,000
Ending balance at Jun. 28, 2013	$ 1,158.0	$ 11.5	$ 1,086.7	$ 0.0	$ 59.8

Background and Basis of Presentation

9 Months Ended

Jun. 28, 2013

Basis of Presentation [Abstract]

Background and Basis of Presentation



1.	Background and Basis of Presentation

Background

Mallinckrodt plc, and its subsidiaries (collectively, "Mallinckrodt" or "the Company"), is a global company that develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients ("API") and diagnostic imaging agents. These products are found in almost every hospital, standalone diagnostic imaging center or pharmacy in the United States ("U.S.") and the Company has a direct sales presence in approximately 50 countries. The Company believes its extensive commercial reach and formulation expertise, coupled with its ability to deal with the highly regulated and technical nature of its business, have created compelling competitive advantages that it anticipates will sustain future revenue growth.

The Company conducts its business in the following two segments:


•	Specialty Pharmaceuticals produces and markets branded and generic pharmaceuticals and API, comprised of medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients; and


•	Global Medical Imaging develops, manufactures and markets contrast media and delivery systems ("CMDS") and radiopharmaceuticals (nuclear medicine).

Mallinckrodt plc was incorporated in Ireland on January 9, 2013 for the purpose of holding the Pharmaceuticals business of Covidien plc ("Covidien"). On June 28, 2013, Covidien shareholders of record received one ordinary share of Mallinckrodt for every eight ordinary shares of Covidien held as of the record date, June 19, 2013, and the Pharmaceuticals business of Covidien was transferred to Mallinckrodt plc, thereby completing its legal separation from Covidien ("the Separation"). On July 1, 2013, Mallinckrodt plc began regular way trading on the New York Stock Exchange under the ticker symbol "MNK."

Basis of Presentation

The accompanying unaudited condensed consolidated and combined financial statements reflect the consolidated financial position of the Company as an independent, publicly-traded company as of June 28, 2013, and as a combined reporting entity of Covidien, including operations relating to Covidien's Pharmaceuticals business, prior to June 28, 2013.

The unaudited condensed consolidated and combined financial statements have been prepared in U.S. dollars and in accordance with accounting principles generally accepted in the U.S. ("GAAP"). The preparation of the unaudited condensed consolidated and combined financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results may differ from those estimates. The unaudited condensed consolidated and combined financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation and, in the opinion of management, all normal recurring adjustments necessary for a fair presentation have been included in the interim results reported. The fiscal year-end balance sheet data were derived from audited combined financial statements, but do not include all of the annual disclosures required by GAAP; accordingly, these unaudited condensed consolidated and combined financial statements should be read in conjunction with the Company's audited annual combined financial statements included in the information statement filed with the U.S. Securities and Exchange Commission ("the SEC") as Exhibit 99.2 to the Company's Current Report on Form 8-K filed on July 1, 2013.

The Company's unaudited condensed combined financial statements for periods prior to June 28, 2013, including the three and nine months ended June 28, 2013, may not be indicative of its future performance and do not necessarily reflect the results of operations, financial position and cash flows that would have been had it operated as an independent, publicly-traded company during the periods presented, including as a result of changes in the Company's capitalization in connection with the Separation. The unaudited condensed combined financial statements for periods prior to June 28, 2013 include expense allocations for certain functions provided by Covidien, including, but not limited to, general corporate expenses related to finance, legal, information technology, human resources, communications, employee benefits and incentives, insurance and stock-based compensation. These expenses have been allocated to the Company on the basis of direct usage when identifiable, with the remainder allocated on the basis of operating expenses, headcount or other measures. The amounts allocated were $14.1 million and $13.1 million during the three months ended June 28, 2013 and June 29, 2012, respectively, and $39.6 million and $35.8 million during the nine months ended June 28, 2013 and June 29, 2012, respectively, and are included within selling, general and administrative expenses. Management considers the bases on which the expenses have been allocated to reasonably reflect the utilization of services provided to, or the benefit received by, the Company during the periods presented; however, the allocations may not reflect the expense the Company would have incurred as an independent, publicly-traded company. Actual costs that may have been incurred if the Company had been a standalone company would depend on a number of factors, including organizational structure, what functions were outsourced or performed by employees, and strategic decisions made in areas such as information technology and infrastructure. The Company is unable to determine what those costs would have been had the Company been independent during the applicable periods. Following the Separation, the Company will perform these functions using its own resources or purchased services, certain of which may be provided by Covidien during a transitional period pursuant to a transition services agreement dated June 28, 2013, between Mallinckrodt and Covidien, particularly in relation to areas outside the U.S. The terms and prices on which such services are rendered may not be as favorable as those that were allocated to the Company by Covidien. The Company also may incur additional costs associated with being an independent, publicly-traded company. These additional anticipated costs are not reflected in the historical combined financial statements.

The unaudited condensed combined balance sheets prior to June 28, 2013 include certain assets and liabilities that have historically been recorded at the Covidien corporate level but are specifically identifiable or otherwise allocable to the Company. The cash and cash equivalents held by Covidien at the corporate level are not specifically identifiable to the Company and, as such, have not been allocated to the Company for periods prior to June 28, 2013. Covidien's debt and related interest expense have not been allocated to the Company since the Company is not the legal obligor of such debt and Covidien's borrowings were not directly attributable to the Company's business. Debt incurred by the Company directly has been included in the unaudited condensed combined financial statements. Intercompany transactions between the Company and Covidien have been included in the condensed combined financial statements and were considered to be effectively settled for cash at the time the transaction was recorded. The total net effect of the settlement of these intercompany transactions was reflected in the unaudited condensed combined statements of cash flows as a financing activity and in the unaudited condensed combined balance sheet as parent company investment.

Prior to June 28, 2013, Covidien's investment in the Pharmaceuticals business is shown as parent company investment in the unaudited condensed combined financial statements. On June 28, 2013, Covidien completed a distribution of one ordinary share of Mallinckrodt for every eight ordinary shares of Covidien. Upon completion of the Separation, the Company had 57,694,885 ordinary shares outstanding at a par value of $0.20 per share. After Separation adjustments were recorded, the remaining parent company investment balance, which includes all earnings prior to the Separation, was transferred to contributed surplus.

Under Irish law, the Company can only pay dividends and repurchase shares out of distributable reserves, as discussed further in the Company's information statement filed with the SEC as Exhibit 99.2 to the Company's Current Report on Form 8-K filed on July 1, 2013. Upon completion of the Separation, the Company did not have any distributable reserves. On July 22, 2013, the Company filed a petition with the High Court of Ireland seeking the court's confirmation of a reduction of the Company's share premium so that it can be treated as distributable for the purposes of Irish law. Net income subsequent to the Separation will be included in retained earnings and will be included in distributable reserves.

Preferred Shares

Mallinckrodt is authorized to issue 500,000,000 preferred shares, par value of $0.20 per share, none of which were issued and outstanding at June 28, 2013 or September 28, 2012. Rights as to dividends, return of capital, redemption, conversion, voting and otherwise with respect to these shares may be determined by Mallinckrodt's board of directors on or before the time of issuance. In the event of the liquidation of the Company, the holders of any preferred shares then outstanding would, if issued on such terms that they carry a preferential distribution entitlement on liquidation, be entitled to payment to them of the amount for which the preferred shares were subscribed and any unpaid dividends prior to any payment to the ordinary shareholders.

Preferred Share Purchase Rights

Pursuant to the rights agreement entered into on June 28, 2013 with Computershare Trust Company, N.A., as the Rights Agent ("the Rights Agreement"), the Company issued one preferred share purchase right (collectively, "the Rights") for each outstanding ordinary share of the Company to shareholders of record on July 9, 2013. The Rights will not be exercisable until ten days after the public announcement that a person or group has become an "Acquiring Person" by obtaining beneficial ownership of 10% or more of the outstanding ordinary shares of Mallinckrodt plc. The Rights will expire on June 28, 2014. The Rights Agreement and the Rights are discussed further in the Company's Form 8-A filed with the SEC on July 1, 2013.

Fiscal Year

The Company reports its results based on a "52-53 week" year ending on the last Friday of September. The third fiscal quarters of 2013 and 2012 ended on June 28, 2013 and June 29, 2012, respectively. Fiscal 2012 consisted of 52 weeks and ended on September 28, 2012. Unless otherwise indicated, the three and nine months ended June 28, 2013 refer to the thirteen and thirty-nine week periods ended June 28, 2013 and the three and nine months ended June 29, 2012 refer to the thirteen and thirty-nine week periods ended June 29, 2012.

Recently Issued Accounting Standards

The Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2011-11 in December 2011, "Disclosures about Offsetting Assets and Liabilities," which was clarified in January 2013 by ASU 2013-01 "Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities." This guidance provides new disclosure requirements about instruments and transactions eligible for offset in the statement of financial position, as well as instruments and transactions subject to an agreement similar to a netting agreement, to enable users of financial statements to understand the effects or potential effects of those arrangements on an entity's financial position. The guidance is effective for the Company in the first quarter of fiscal 2014. The Company is still assessing the impact of the pronouncement but does not expect it will have a material impact on its financial condition, results of operations and cash flows.

FASB issued ASU 2013-02, "Reporting Amounts Classified out of Accumulated Other Comprehensive Income," in February 2013. This guidance requires an entity to present, either on the face of the statement of income or separately in the notes to the financial statements, the effects on net income of significant amounts reclassified out of each component of accumulated other comprehensive income, if those amounts are required to be reclassified to net income in their entirety in the same reporting period. For other amounts not required to be reclassified to net income in their entirety, an entity is required to cross-reference to other disclosures that provide additional details about those amounts. The guidance is effective for the Company in the first quarter of fiscal 2014. The Company is still assessing the impact of the pronouncement but does not expect it will have a material impact on its financial condition, results of operations and cash flows.

FASB issued ASU 2013-04, "Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date," in February 2013. This update provides guidance for the recognition, measurement and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation is fixed at the reporting date, except for obligations addressed within existing guidance. An entity is required to measure those obligations as the sum of the amount the entity has agreed to pay on the basis of its arrangement among its co-obligors, and any additional amounts it expects to pay on behalf of its co-obligors. The guidance also requires the entity to disclose the nature and amount of those obligations. The guidance is effective for the Company in the first quarter of fiscal 2015. The Company is still assessing the impact of the pronouncement but does not expect it will have a material impact on its financial condition, results of operations and cash flows.

Acquisitions

9 Months Ended

Jun. 28, 2013

Business Combinations [Abstract]

Acquisitions



2.	Acquisitions

CNS Therapeutics

On October 1, 2012, the Company's Specialty Pharmaceuticals segment acquired all the outstanding equity of CNS Therapeutics, Inc. ("CNS Therapeutics"), a specialty pharmaceuticals company focused on developing and commercializing intrathecal products for site-specific administration to the central nervous system to treat neurological disorders and intractable chronic pain, for total consideration of $95.0 million. The total consideration was comprised of an upfront cash payment of $88.1 million (net of cash acquired of $3.6 million) and the fair value of contingent consideration of $6.9 million. This contingent consideration, which could potentially total a maximum of $9.0 million, is discussed further in note 15. The acquisition of CNS Therapeutics expanded the Company's branded pharmaceuticals portfolio and supports the Company's strategy of leveraging its therapeutic expertise and core capabilities in manufacturing, regulatory and commercialization to serve patients. With the acquisition, the Company now offers products for use in the management of severe spasticity of cerebal or spinal origin with a research and development pipeline of additional presentations and strengths and pain products for intrathecal administration.

The following amounts represent the final allocation of the fair value of the identifiable assets acquired and liabilities assumed:



Current assets ⁽¹⁾	$	13.3
Intangible assets	91.9
Goodwill (non-tax deductible) ⁽²⁾	24.5
Total assets acquired	129.7
Current liabilities	4.0
Deferred tax liabilities (non-current)	27.1
Contingent consideration (non-current)	6.9
Total liabilities assumed	38.0
Net assets acquired	$	91.7


(1)	This amount includes $3.3 million of accounts receivable, which is also the gross contractual value. As of the acquisition date, the fair value of accounts receivable approximated carrying value.


(2)	Goodwill relates to the Company's ability to exploit CNS Therapeutics' technologies.

The following reconciles the total consideration to net assets acquired:



Total consideration	$	95.0
Plus cash assumed in acquisition	3.6
Less: contingent consideration	(6.9		)
Net assets acquired	$	91.7

Intangible assets acquired consist of the following:



	Amount		Weighted-Average Amortization Period
Completed technology	$	73.1	13 years
Trademark	0.2		3 years
In-process research and development	18.6		Non-Amortizable
	$	91.9

The in-process research and development projects primarily relate to certain intrathecal pain products. As of the date of acquisition, these pain products were in various stages of development, with further development, testing, clinical trials and regulatory submission required in order to bring them to market. At the acquisition date, the total cost to complete these products was estimated to be approximately $18.0 million. The Company expects that regulatory approvals will occur between 2015 and 2018. The valuation of the in-process research and development was determined using, among other factors, appraisals primarily based on the discounted cash flow method. The cash flows were discounted at a 35% rate, which was considered commensurate with the risks and stages of development of the pain products. Future residual cash flows that could be generated from the products were determined based upon management's estimate of future revenue and expected profitability of the products. These projected cash flows were then discounted to their present values taking into account management's estimate of future expenses that would be necessary to bring the products to completion.

The unaudited condensed combined statements of income for the three and nine months ended June 28, 2013 contained $7.5 million and $20.8 million, respectively, of net sales of intrathecal products added to our portfolio from the CNS Therapeutics acquisition. Acquisition and integration costs included in the periods presented were not material. The Company does not believe that the results of operations for the periods presented would have been materially different had the acquisition taken place on October 1, 2011.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

+ Details

Restructuring and Related Charges, Net

9 Months Ended

Jun. 28, 2013

Restructuring Charges [Abstract]

Restructuring and Related Charges, Net



3.	Restructuring and Related Charges

During fiscal 2011 and fiscal 2009, Covidien launched restructuring programs designed to improve its cost structure, which also applied to its Pharmaceuticals business. The 2009 program is substantially completed. The Company expects to incur charges under the 2011 program as the specific actions required to execute on these initiatives are identified and approved, most of which are expected to be incurred by the end of fiscal 2014.

Net restructuring and related charges by segment are as follows:



	Three Months Ended						Nine Months Ended
	June 28, 2013			June 29, 2012			June 28, 2013			June 29, 2012
Specialty Pharmaceuticals	$	7.0		$	2.3		$	13.6		$	10.2
Global Medical Imaging	5.1			4.1			6.4			7.1
Restructuring and related charges, net	12.1			6.4			20.0			17.3
Less: accelerated depreciation	(0.8		)	(1.4		)	(2.1		)	(6.8		)
Restructuring charges, net	$	11.3		$	5.0		$	17.9		$	10.5

Net restructuring and related charges are comprised of the following:



	Three Months Ended						Nine Months Ended
	June 28, 2013			June 29, 2012			June 28, 2013			June 29, 2012
2011 Covidien program	$	11.6		$	6.3		$	18.8		$	17.1
2009 Covidien program	0.2			0.1			0.1			0.2
Acquisitions	0.3			—			1.1			—
Total programs	12.1			6.4			20.0			17.3
Less: non-cash charges, including accelerated depreciation	(0.7		)	(1.5		)	(2.1		)	(6.9		)
Total charges expected to be settled in cash	$	11.4		$	4.9		$	17.9		$	10.4

The following table summarizes cash activity for restructuring reserves, substantially all of which relates to employee severance and benefits under the 2011 Covidien program:




Balance at September 28, 2012	$	8.9
Charges	20.0
Changes in estimate	(2.1		)
Cash payments	(9.7		)
Reclassifications ⁽¹⁾	(1.0		)
Balance at June 28, 2013	$	16.1


(1)	Represents the reclassification of pension and other postretirement benefits from restructuring reserves to pension and postretirement obligations, and the transfer of certain restructuring liabilities in conjunction with the Separation.

Net restructuring and related charges, including associated asset impairments, incurred cumulative to date related to the 2011 Covidien program are as follows:




Specialty Pharmaceuticals	$	29.7
Global Medical Imaging	20.0
	$	49.7

Substantially all of the restructuring reserves are included in accrued and other current liabilities on the Company's unaudited condensed consolidated and combined balance sheets.

Earnings (loss) per Share

9 Months Ended

Jun. 28, 2013

Earnings Per Share [Abstract]

Earnings (loss) per Share



4.	Earnings (Loss) per Share

The computations of basic and diluted earnings (loss) per share for all periods presented in the unaudited condensed combined statements of income are calculated using the number of ordinary shares of Mallinckrodt outstanding on June 28, 2013, immediately following the distribution of one ordinary share of Mallinckrodt for every eight ordinary shares of Covidien. The dilutive effect of the Company's share-based awards that were issued as a result of the conversion of Covidien share-based awards with the Separation, as well as for future Company grants, will be included in the computation of diluted earnings per share in periods subsequent to June 28, 2013.

Inventories

9 Months Ended

Jun. 28, 2013

Inventory, Net [Abstract]

Inventories



5.	Inventories

Inventories are comprised of the following at the end of each period:



	June 28, 2013		September 28, 2012
Raw materials and supplies	$	67.8	$	74.1
Work in process	188.9		184.7
Finished goods	166.4		176.5
Inventories	$	423.1	$	435.3

Goodwill and Intangible Assets

9 Months Ended

Jun. 28, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets



6.	Goodwill and Intangible Assets

The changes in the carrying amount of goodwill by segment were as follows:



	Specialty Pharmaceuticals		Global Medical Imaging		Total
Goodwill at September 28, 2012	$	287.8	$	219.7	$	507.5
Acquisitions	24.5		—		24.5
Goodwill at June 28, 2013	$	312.3	$	219.7	$	532.0

The gross carrying amount and accumulated amortization of intangible assets at the end of each period were as follows:



	June 28, 2013				September 28, 2012
	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Amortizable:
Completed technology	$	449.2	$	190.9	$	376.1	$	173.7
Licenses	191.1		76.3		191.1		67.1
Trademarks	7.9		3.7		7.7		3.5
Total	$	648.2	$	270.9	$	574.9	$	244.3
Non-Amortizable:
Trademarks	$	35.0			$	35.0
In-process research and development	18.6				—
Total	$	53.6			$	35.0

Intangible asset amortization expense was $8.9 million and $6.8 million during the three months ended June 28, 2013 and June 29, 2012, respectively, and $26.6 million and $20.3 million during the nine months ended June 28, 2013 and June 29, 2012, respectively. The estimated aggregate amortization expense on intangible assets owned by the Company is expected to be as follows:




Remainder of fiscal 2013	$	8.8
Fiscal 2014	35.4
Fiscal 2015	35.4
Fiscal 2016	35.3
Fiscal 2017	33.9

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Property, Plant and Equipment

9 Months Ended

Jun. 28, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment



7.	Property, Plant and Equipment

The gross carrying amount and accumulated depreciation of property, plant and equipment at the end of each period was as follows:



	June 28, 2013			September 28, 2012
Property, plant and equipment, gross	$	1,826.5		$	1,751.4
Less: accumulated depreciation	(848.6		)	(806.2		)
Property, plant and equipment, net	$	977.9		$	945.2

Depreciation expense for property, plant and equipment was $25.3 million and $24.5 million during the three months ended June 28, 2013 and June 29, 2012, respectively, and $72.8 million and $74.5 million during the nine months ended June 28, 2013 and June 29, 2012, respectively.

Debt

9 Months Ended

Jun. 28, 2013

Debt Disclosure [Abstract]

Debt



8.	Debt

Debt was comprised of the following at the end of each period:



	June 28, 2013		September 28, 2012
Current maturities of long-term debt:
Capital lease obligation	$	1.3	$	1.3
Note payable	0.1		—
Total current debt	1.4		1.3
Long-term debt:
3.50% notes due April 2018	299.9		—
4.75% notes due April 2023	598.1		—
7.00% debentures due December 2013⁽¹⁾	—		5.8
8.00% debentures due March 2023⁽²⁾	8.0		—
9.50% debentures due May 2022⁽²⁾	10.4		—
Capital lease obligation	2.1		3.1
Total long-term debt	918.5		8.9
Total debt	$	919.9	$	10.2


(1)	Under the terms of the separation and distribution agreement entered into with Covidien on June 28, 2013, the 7.00% debentures due December 2013 were retained by Covidien.


(2)	Under the terms of the separation and distribution agreement entered into with Covidien on June 28, 2013, the 8.00% and 9.50% debentures due in March 2023 and May 2022, respectively, were transferred to the Company.

In November 2012, Mallinckrodt International Finance S.A. ("MIFSA") was formed as a wholly-owned subsidiary of Covidien in connection with the Separation. MIFSA is a holding company established to own, directly or indirectly, substantially all of the operating subsidiaries of the Company, to issue debt securities and to perform treasury operations. At the time of the Separation, MIFSA became a wholly-owned subsidiary of the Company.

In March 2013, MIFSA entered into a $250 million five-year senior unsecured revolving credit facility that matures in June 2018 ("the Credit Facility"). Borrowings under the Credit Facility will initially bear interest at LIBOR plus 1.50% per annum (subject to adjustment pursuant to a ratings-based pricing grid). The Credit Facility contains a $150 million letter of credit sublimit. The Credit Facility is subject to an initial annual facility fee of 0.25%, which is also subject to adjustment pursuant to a ratings-based pricing grid, and the fee applied to outstanding letters of credit is based on the interest rate applied to borrowings. The Credit Facility agreement contains customary affirmative and negative covenants, including a financial maintenance covenant that limits the Company's ratio of debt to earnings before interest, income taxes, depreciation and amortization, as adjusted for certain items, and another financial maintenance covenant that requires the Company's ratio of earnings before interest, income taxes, depreciation and amortization, as adjusted for certain items, to interest expense to exceed certain thresholds. Other nonfinancial covenants restrict, among other things, the Company's ability to create liens, the ability of the non-guarantor subsidiaries to incur additional indebtedness and the ability of the Company to merge or consolidate with any other person or sell or convey certain of its assets to any one person. MIFSA was not permitted to draw upon the Credit Facility until certain conditions were met, including completion of the Separation and Mallinckrodt plc's guaranty of MIFSA's obligations under the Credit Facility. These conditions have been satisfied as of June 28, 2013; however, there were no borrowings or letters of credit outstanding under the Credit Facility at that time.

In April 2013, MIFSA issued $300 million aggregate principal amount of 3.50% senior unsecured notes due April 2018 and $600 million aggregate principal amount of 4.75% senior unsecured notes due April 2023 (collectively, "the Notes"). Mallinckrodt plc has fully and unconditionally guaranteed the Notes on an unsecured and unsubordinated basis as of the completion of the Separation. The Notes are subject to an indenture which contains covenants limiting the ability of MIFSA, its restricted subsidiaries (as defined in the Notes) and Mallinckrodt plc, as guarantor, to incur certain liens or enter into sale and lease-back transactions. It also restricts Mallinckrodt plc and MIFSA's ability to merge or consolidate with any other person or sell or convey all or substantially all of their assets to any one person. MIFSA may redeem all of the Notes at any time, and some of the Notes from time to time, at a redemption price equal to the principal amount of the Notes redeemed plus a make-whole premium. MIFSA will pay interest on the Notes semiannually in arrears on April 15 and October 15 of each year, commencing on October 15, 2013. The net proceeds to MIFSA from the issuance and sale of the Notes was $889.3 million, the majority of which was retained by Covidien per the terms of the separation and distribution agreement entered into with Covidien on June 28, 2013 ("the Separation and Distribution Agreement"). The Notes were issued and sold in a private placement; however, MIFSA is required to register the Notes with the SEC within one year of the issuance of the Notes.

As of June 28, 2013, the Company was, and expects to remain, in compliance with the provisions and covenants associated with its Credit Agreement, the Notes and its other debt agreements.

Retirement Plans

9 Months Ended

Jun. 28, 2013

Compensation and Retirement Disclosure [Abstract]

Retirement Plans



9.	Retirement Plans

The net periodic benefit cost for the Company's defined benefit pension plans was as follows:



	Three Months Ended						Nine Months Ended
	June 28, 2013			June 29, 2012			June 28, 2013			June 29, 2012
Service cost	$	1.2		$	1.3		$	3.6		$	3.9
Interest cost	4.6			5.4			13.7			16.1
Expected return on plan assets	(7.4		)	(6.2		)	(22.1		)	(18.5		)
Amortization of net actuarial loss	3.0			2.9			9.0			8.7
Amortization of prior service cost	0.1			0.2			0.4			0.5
Plan settlements loss	5.4			—			5.4			—
Net periodic benefit cost	$	6.9		$	3.6		$	10.0		$	10.7

During the nine months ended June 28, 2013, Covidien made a $37.5 million voluntary contribution to the Company's pension plans. The Company does not currently expect to make any further contributions during fiscal 2013.

The net periodic benefit credit for postretirement benefit plans for the three months ended June 28, 2013 and June 29, 2012 was $1.6 million and $1.5 million, respectively, and for the nine months ended June 28, 2013 and June 29, 2012 was $4.7 million and $4.4 million, respectively. The components of the credit were not material.

Share Plans

9 Months Ended

Jun. 28, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share Plans



10.	Share Plans

Total share-based compensation cost was $4.6 million and $2.6 million for the three months ended June 28, 2013 and June 29, 2012, respectively, and was $11.4 million and $8.3 million for the nine months ended June 28, 2013 and June 29, 2012, respectively. These amounts are generally included within selling, general and administrative expenses in the unaudited condensed combined statements of income; however, the incremental fair value associated with the conversion of Covidien equity awards into Mallinckrodt equity awards discussed below is included in separation costs.

Conversion of Covidien Equity Awards

Prior to the Separation, all employee incentive equity awards were granted by Covidien. At the time of Separation, the restricted share units and share options granted to Mallinckrodt employees prior to June 28, 2013 were converted into restricted share units and share options, respectively, of Mallinckrodt, and all of the performance share awards granted to Mallinckrodt employees were converted into restricted share units of Mallinckrodt (collectively, "the Conversion"). Mallinckrodt incentive equity awards issued upon completion of the Conversion and the related weighted-average grant date fair value is presented below:

Share Options

A summary of the status of the Company's share option awards upon completion of the Conversion on June 28, 2013 is presented below:



	Shares Options	Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at June 28, 2013	2,399,822	$	35.94	3.8	$	22.9
Exercisable at June 28, 2013	550,097	30.94		2.4	8.0

The Conversion resulted in a modification of the previously issued share option awards. The Company compared the aggregate fair value of the awards immediately before and immediately after the Separation. Generally, the fair value of the awards immediately after the Separation was higher than the awards immediately before, primarily due to the elimination of Covidien's dividend yield assumption and the Company's higher volatility as compared to Covidien. The incremental fair value for vested awards was recognized immediately within separation costs, as the incremental fair value is directly attributable to the Separation, and the fair value for unvested awards will be recognized on a straight-line basis over the remaining vesting period of the applicable awards, also within separation costs.

The weighted-average assumptions used in the Black-Scholes pricing model for determining the fair value of the share option awards immediately before and immediately after the Separation were as follows:



	Pre- Separation			Post- Separation
Expected share price volatility	26		%	32		%
Risk-free interest rate	0.99		%	0.99		%
Expected annual dividend per share	1.65		%	—
Expected life of options (in years)	3.8			3.8
Fair value per option	$	18.04		$	16.51
Share option awards	1,745,258			2,399,822

Restricted Share Unit Awards

The Conversion resulted in a modification of the previously issued restricted share unit awards. The Company compared the aggregate fair value of the awards immediately before and immediately after the Separation. The Conversion did not result in incremental fair value.

Performance Share Unit Awards

The Conversion resulted in a modification of the previously issued performance share unit awards. The Company compared the aggregate fair value of the awards immediately before and immediately after the Separation. The fair value of the awards was higher after the Conversion as the performance factor utilized to convert the award was higher than what had previously been estimated. The incremental fair value was recognized immediately within separation costs for the service period to date and the remaining incremental fair value will be recognized over the remaining vesting period, also within separation costs.

Related Party Transactions

9 Months Ended

Jun. 28, 2013

Related Party Transactions



11.	Related Party Transactions

Prior to the completion of the Separation on June 28, 2013, the Company was part of Covidien and, as such, transactions between Covidien and the Company were considered related party transactions. As discussed in note 1, these intercompany transactions are included in the unaudited condensed combined financial statements and were considered to be effectively settled for cash at the time the transaction was recorded. The continuing relationship between Covidien and the Company is primarily governed through agreements entered into as part of the Separation. The Separation and Distribution Agreement, tax matters agreement and transition services agreement were filed with the SEC as Exhibits 2.1, 10.1 and 10.3, respectively, to the Company's Current Report on Form 8-K filed on July 1, 2013. The following discusses the related party transactions and those agreements.

Related Party Sales and Purchases

During the three months ended June 28, 2013 and June 29, 2012, the Company sold inventory to Covidien in the amount of $13.5 million and $14.9 million, respectively, which is included in net sales in the unaudited condensed combined statements of income. During the nine months ended June 28, 2013 and June 29, 2012, the Company sold inventory to Covidien in the amount of $39.4 million and $42.8 million, respectively. The Company also purchases inventories from Covidien. The Company recognized cost of sales from these inventory purchases of $9.6 million and $8.1 million during the three months ended June 28, 2013 and June 29, 2012, respectively, and $31.6 million and $25.1 million during the nine months ended June 28, 2013 and June 29, 2012, respectively. As of June 28, 2013 and September 28, 2012, the aggregate amount of inventories purchased from Covidien that remained on the Company's unaudited condensed consolidated and combined balance sheets was $8.1 million and $4.5 million, respectively.

Allocated Expenses

As discussed in note 1, the unaudited condensed combined financial statements for periods prior to June 28, 2013 include expense allocations for certain functions provided by Covidien, including, but not limited to, general corporate expenses related to finance, legal, information technology, human resources, communications, employee benefits and incentives, insurance and share-based compensation. These expenses have been allocated to the Company on the basis of direct usage when identifiable, with the remainder allocated on the basis of operating expenses, headcount or other measures. The amounts allocated were $14.1 million and $13.1 million during the three months ended June 28, 2013 and June 29, 2012, respectively, and $39.6 million and $35.8 million during the nine months ended June 28, 2013 and June 29, 2012, respectively, and are included within selling, general and administrative expenses.

Balance Sheet Impacts

Prior to the Separation, intercompany transactions between the Company and Covidien were considered to be effectively settled for cash at the time the transaction was recorded and were presented within parent company investment in the unaudited condensed combined balance sheet. However, at the completion of the Separation on June 28, 2013, certain transactions remained unsettled and were reclassified from parent company investment and included within the assets and liabilities of the Company. The condensed consolidated balance sheet as of June 28, 2013 includes $22.3 million of amounts due to the Company from Covidien, within prepaid expenses and other current assets, and $61.9 million of amounts the Company owes Covidien, included within accrued and other liabilities.

In connection with the Separation, the Company recorded separation related adjustments within parent company investment, which represent transfers of certain assets and liabilities with Covidien pursuant to the Separation and Distribution Agreement. The Company has used available information to develop its best estimates for certain assets and liabilities related to the Separation. In limited instances, final determination of the balances will be made in subsequent periods. Any adjustments, if necessary, are not expected to be material and will be recorded through shareholders' equity in subsequent periods when determined.

Separation and Distribution Agreement

On June 28, 2013, the Company entered into a Separation and Distribution Agreement and other agreements with Covidien to effect the Separation and provide a framework for the Company's relationships with Covidien after the Separation. These agreements govern the relationship between Mallinckrodt and Covidien subsequent to the Separation and provide for the assignment to Mallinckrodt of certain of Covidien's assets, liabilities and obligations attributable to periods prior to the Separation.

In general, each party to the Separation and Distribution Agreement assumed liability for all pending, threatened and unasserted legal matters related to its own business or its assumed or retained liabilities and will indemnify the other party for any liability to the extent arising out of, or resulting from, such assumed or retained legal matters.

The Separation and Distribution Agreement provided for the initial cash capitalization of Mallinckrodt in the amount of approximately $168 million at June 28, 2013. The Separation and Distribution Agreement also provided for an adjustment payment to compensate either Mallinckrodt or Covidien, as applicable, to the extent that the aggregate of the Company's cash, indebtedness and specified working capital accounts as of June 28, 2013 ("the Distribution Date"), as well as the capital expenditures made with respect to the Company's business during fiscal 2013 through the Distribution Date, deviates from a target. The target was calculated pursuant to a formula set forth in the Separation and Distribution Agreement, which assumed the Distribution Date would be June 28, 2013, that the Pharmaceuticals business was conducted in the ordinary course through that date and that the Company would have approximately $168 million of cash upon completion of the distribution. The Separation and Distribution Agreement also provided that an adjustment payment will only be payable if the amount of the adjustment payment exceeds $20 million (in which case the entire amount will be paid).

Tax Matters Agreement

In connection with the Separation, Mallinckrodt entered into a tax matters agreement ("the Tax Matters Agreement") with Covidien that generally will govern Covidien's and Mallinckrodt's respective rights, responsibilities and obligations after the Separation with respect to certain taxes, including ordinary course of business taxes and taxes, if any, incurred as a result of any failure of the distribution of Mallinckrodt shares to qualify as a tax-free distribution for U.S. federal income tax purposes within the meaning of Section 355 of the U.S. Internal Revenue Code, or other applicable tax law, or any failure of certain internal transactions undertaken in anticipation of the distribution to qualify for tax-free or tax-favored treatment under the applicable tax law. The Company expects, with certain exceptions, to be responsible for the payment of all taxes attributable to Mallinckrodt or its subsidiaries for taxable periods beginning on or after September 29, 2012. For periods prior to September 29, 2012, the Company is subject to a $200 million liability limitation, net of any benefits, as prescribed by the Tax Matters Agreement. To the extent that the Company's liability for such taxes, net of any tax benefits, does not exceed $200 million, it may be responsible for additional taxes attributable to periods prior to September 29, 2012, taxes related to the Separation and a percentage of any taxes arising from the Separation failing to qualify for tax-free or tax-favored treatment through no fault of Covidien or the Company. The Tax Matters Agreement also assigns rights and responsibilities for administrative matters, such as the filing of returns, payment of taxes due, retention of records, tax reporting practices and conduct of audits, examinations or similar proceedings. In addition, the Tax Matters Agreement provides for cooperation and information sharing with respect to tax matters.

The Tax Matters Agreement also contains restrictions on the Company's ability to take actions without Covidien's consent that could cause the Separation or certain internal transactions undertaken in anticipation of the Separation to fail to qualify as tax-free or tax-favored transactions under applicable tax law. These transactions include, but are not limited to, entering into, approving or allowing any transaction that results in a change in ownership of more than 35% of Mallinckrodt's shares; any merger, consolidation, scheme of arrangement, liquidation or partial liquidation, or any approval or allowance of such transaction with respect to certain of the Company's subsidiaries; the cessation or transfer of certain business activities; the sale, issuance or other disposition of any equity interest in certain of the Company's subsidiaries; a sale or other disposition of a substantial portion of the Company's assets or a substantial portion of the assets of certain of the Company's subsidiaries; extraordinary distributions by or to certain of the Company's subsidiaries; or engaging in certain internal transactions. These restrictions will all apply for the two-year period after the Separation and in some cases will apply for periods as long as five years following the Separation. Any taxes imposed on the other party attributable to certain post-distribution actions taken by or in respect of the responsible party or its shareholders that result in failure of the Separation or internal transactions to qualify as tax-free or tax-favored transactions are the responsibility of the party at fault, regardless of whether the actions occur more than two years after the distribution, or whether Covidien consents to such actions. Any actions of the Company or its shareholders that directly give rise to additional taxes are not subject to the $200 million threshold noted previously.

Transition Services Agreement

Mallinckrodt and Covidien entered into a transition services agreement in connection with the Separation pursuant to which Mallinckrodt and Covidien will provide each other, on an interim and transitional basis, various services including, but not limited to, treasury administration, information technology services, non-exclusive distribution and importation services for our products in certain countries outside the U.S., regulatory, general administrative services and other support services. The agreed-upon charges for such services are generally intended to allow the servicing party to recover all out-of-pocket costs and expenses, and include a predetermined profit margin.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Guarantees

9 Months Ended

Jun. 28, 2013

Guarantees [Abstract]

Guarantees



12.	Guarantees

In disposing of assets or businesses, the Company has historically provided representations, warranties and indemnities to cover various risks and liabilities, including unknown damage to the assets, environmental risks involved in the sale of real estate, liability to investigate and remediate environmental contamination at waste disposal sites and manufacturing facilities, and unidentified tax liabilities related to periods prior to disposition. Except as discussed below, the Company generally does not have the ability to estimate the potential liability from such indemnities because they relate to unknown conditions. However, the Company has no reason to believe that these uncertainties would have a material adverse effect on its financial condition, results of operations and cash flows.

In connection with the sale of the Specialty Chemicals business (formerly known as Mallinckrodt Baker) in fiscal 2010, the Company agreed to indemnify the purchaser with respect to various matters, including certain environmental, health, safety, tax and other matters. The indemnification obligations relating to certain environmental, health and safety matters have a term of 17 years, while some of the other indemnification obligations have an indefinite term. The amount of the liability relating to all of these indemnification obligations included in other liabilities on the Company's unaudited condensed consolidated and combined balance sheets at both June 28, 2013 and September 28, 2012 was $22.4 million, of which $18.3 million related to environmental, health and safety matters. The value of the environmental, health and safety indemnity was measured based on the probability-weighted present value of the costs expected to be incurred to address environmental, health and safety claims made under the indemnity. The aggregate fair value of these indemnification obligations did not differ significantly from their aggregate carrying value at June 28, 2013 and September 28, 2012. As of June 28, 2013, the maximum future payments the Company could be required to make under these indemnification obligations was $75.5 million. The Company was required to pay $30.0 million into an escrow account as collateral to the purchaser, of which $23.5 million and $24.5 million remained in other assets on the unaudited condensed consolidated and combined balance sheets at June 28, 2013 and September 28, 2012, respectively.

The Company has recorded liabilities for known indemnification obligations included as part of environmental liabilities, which are discussed in note 13. In addition, the Company is liable for product performance; however in the opinion of management, such obligations will not have a material adverse effect on the Company's financial condition, results of operations and cash flows.

The Company is required to provide the U.S. Nuclear Regulatory Commission financial assurance demonstrating its ability to fund the decommissioning of its Maryland Heights, Missouri radiopharmaceuticals production facility upon closure, though the Company does not intend to close this facility. The Company has provided this financial assurance in the form of a $58.0 million surety bond.

In addition, as of June 28, 2013, the Company had a $21.1 million letter of credit to guarantee decommissioning costs associated with its Saint Louis, Missouri plant. As of June 28, 2013, the Company had various other letters of credit and guarantee and surety bonds totaling $27.3 million.

In addition, the Separation and Distribution Agreement provides for cross-indemnities principally designed to place financial responsibility of the obligations and liabilities of the Company's business with the Company and financial responsibility for the obligations and liabilities of Covidien's remaining business with Covidien, among other indemnities.

Commitments and Contingencies

9 Months Ended

Jun. 28, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies



13.	Commitments and Contingencies

The Company is subject to various legal proceedings and claims, including patent infringement claims, product liability matters, environmental matters, employment disputes, contractual disputes and other commercial disputes, including those described below. The Company believes that these legal proceedings and claims likely will be resolved over an extended period of time. Although it is not feasible to predict the outcome of these matters, the Company is of the opinion that their ultimate resolution will not have a material adverse effect on the Company's financial condition, results of operations and cash flows.

Governmental Proceedings

On January 7, 2009, the Company received a subpoena from the U.S. Attorney's Office for the Northern District of California requesting production of documents relating to the sales and marketing of its Tofranil-PM™, Restoril™ and Magnacet products. In June 2013, the Company agreed to settlement terms in this proceeding providing for a cash payment by the Company of $3.5 million, which is consistent with the Company's previously established accrual.

On November 30, 2011 and October 22, 2012, the Company received subpoenas from the U.S. Drug Enforcement Administration requesting production of documents relating to its suspicious order monitoring programs. The Company is complying as required by the terms of the subpoenas. While it is not possible at this time to determine with certainty the outcome of these proceedings, the Company believes that the ultimate resolution will not have a material adverse effect on its financial condition, results of operations and cash flows.

Patent/Antitrust Litigation

Tyco Healthcare Group LP, et al. v. Mutual Pharmaceutical Company, Inc. The Company filed a patent infringement suit in the U.S. District Court for the District of New Jersey against Mutual Pharmaceutical Co., Inc., et al. (collectively, "Mutual") on March 20, 2007 pursuant to procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984, after Mutual submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration ("FDA") seeking to sell a generic version of the Company's 7.5 mg Restoril™ sleep aid product. Mutual also filed antitrust and unfair competition counterclaims. The patents at issue have since expired or been found invalid. On January 18, 2013, the trial court issued an opinion and order granting the Company's motion for summary judgment regarding Mutual's antitrust and unfair competition counterclaims. On May 1, 2013, Mutual appealed this decision to the U.S. Court of Appeals for the Federal Circuit. While it is not possible at this time to determine with certainty the ultimate outcome of the counterclaims, the Company believes that the final resolution of the claims will not have a material adverse effect on the Company's financial condition, results of operations and cash flows.

Pricing Litigation

Two cases were brought against the Company that allege generally that the Company and numerous other pharmaceuticals companies reported false pricing information in connection with certain drugs that are reimbursable under Medicaid, resulting in overpayment by state Medicaid programs for those drugs. These cases, brought by state Attorneys General in Utah and Louisiana, generally seek monetary damages and attorneys' fees. The Company is named as a defendant in State of Utah v. Actavis US, Inc., et al. filed May 8, 2008, which is pending in the Third Judicial Circuit of Salt Lake County, Utah and in State of Louisiana v. Abbott Laboratories Inc., et al. filed November 3, 2010, which was pending in the 19th Judicial District, Parish of East Baton Rouge, Louisiana. In May 2013, the Company agreed to terms of settlement with the Attorney General for the State of Louisiana resolving all claims in State of Louisiana v. Abbott Laboratories Inc., et al. The settlement did not have a material impact on the Company's unaudited condensed consolidated and combined financial statements. The Utah case is pending and the Company intends to contest that case and to explore other options as appropriate. While it is not possible at this time to determine with certainty the outcome of the case, the Company believes that the ultimate resolution will not have a material adverse effect on its financial condition, results of operations and cash flows.

Environmental Remediation and Litigation Proceedings

The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites, including those described below. The ultimate cost of site cleanup and timing of future cash outlays is difficult to predict, given the uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations and alternative cleanup methods. The Company concluded that, as of June 28, 2013, it was probable that it would incur remedial costs in the range of $48.1 million to $85.6 million. The Company concluded that, as of June 28, 2013, the best estimate within this range was $48.2 million, of which $9.0 million was included in accrued and other current liabilities and the remainder was included in environmental liabilities on the unaudited condensed consolidated balance sheet at June 28, 2013.

Orrington, Maine. The Company was a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982. As such, the Company was responsible for the costs of completing an environmental site investigation required by the U.S. Environmental Protection Agency ("EPA") and the Maine Department of Environmental Protection. Further information and details on the history of the case can be found in the information statement filed with the SEC as Exhibit 99.2 to the Company's Current Report on Form 8-K filed on July 1, 2013. The Company estimated that, as of September 28, 2012, the cost to comply with the proposed remediation alternatives at this site ranged from $95.8 million to $170.3 million. At September 28, 2012, estimated future investigation and remediation costs of $95.8 million were accrued for this site.

In accordance with the Separation and Distribution Agreement, this liability was retained by Covidien, and, therefore, this liability was removed from environmental liabilities as of June 28, 2013, the date the Separation was completed. As the Company no longer manages this case, it will not continue to update its status for further developments.

Penobscot River and Bay. Since April 2000, the Company had been involved in the lawsuit, Maine People's Alliance and Natural Resources Defense Council, Inc. v. HoltraChem Manufacturing Company, LLC and Mallinckrodt US LLC, filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People's Alliance. Plaintiffs sought an injunction requiring the Company to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary. Further information and details on the history of this case can be found in the information statement filed with the SEC as Exhibit 99.2 to the Company's Current Report on Form 8-K filed on July 1, 2013.

Crab Orchard National Wildlife Refuge Superfund Site, near Marion, Illinois. The Company is a successor in interest to International Minerals and Chemicals Corporation ("IMC"). Between 1967 and 1982, IMC leased portions of the Additional and Uncharacterized Sites ("AUS") Operable Unit at the Crab Orchard Superfund Site ("the Site") from the government and manufactured various explosives for use in mining and other operations. In March 2002, the Department of Justice, the U.S. Department of the Interior and the EPA (together, "the Government Agencies") issued a special notice letter to General Dynamics Ordnance and Tactical Systems, Inc. ("General Dynamics"), one of the other potentially responsible parties ("PRPs") at the Site, to compel General Dynamics to perform the remedial investigation and feasibility study ("RI/FS") for the AUS Operable Unit. General Dynamics negotiated an Administrative Order on Consent with the Government Agencies to conduct an extensive RI/FS at the Site under the direction of the U.S. Fish and Wildlife Service. General Dynamics asserted in August 2004 that the Company is jointly and severally liable, along with approximately eight other lessees and operators at the AUS Operable Unit, for alleged contamination of soils and groundwater resulting from historic operations, and has threatened to file a contribution claim against the Company and other parties for recovery of its costs incurred in connection with the RI/FS activities being conducted at the AUS Operable Unit. The Company and other PRPs who received demand letters from General Dynamics have explored settlement alternatives, but have not reached settlement to date. The Company and other PRPs are awaiting completion of the RI/FS by General Dynamics before the initiation of formal PRP negotiations to address resolution of these alleged claims. While it is not possible at this time to determine with certainty the ultimate outcome of this case, the Company believes that the final resolution of all known claims, after taking into account amounts already accrued, will not have a material adverse effect on the Company's financial condition, results of operations and cash flows.

Mallinckrodt Veterinary, Inc., Millsboro, Delaware. The Company previously operated a plant in Millsboro, Delaware ("the Millsboro Site") that manufactured various animal healthcare products. In 2005, the Delaware Department of Natural Resources and Environmental Control found trichloroethylene ("TCE") in the Millsboro public water supply at levels that exceeded the federal drinking water standards. Further investigation to identify the TCE plume in the ground water indicated that the plume has extended to property owned by a third party near the Millsboro Site. The Company, and other former owners, assumed responsibility for the Millsboro Site cleanup under the Alternative Superfund Program administered by the EPA. The Company and other PRPs entered into an Administrative Order on Consent with the EPA on May 10, 2010, which was subsequently amended in November 2010 and January 2011, to investigate the potential source of TCE contamination and to evaluate options to abate, mitigate and/or eliminate the release or threat of release of hazardous substances at the Millsboro Site. The Company, along with other parties, continues to conduct the studies and prepare remediation plans in accordance with the amended Administrative Order on Consent. While it is not possible at this time to determine with certainty the ultimate outcome of this matter, the Company believes that the final resolution of all known claims, after taking into account amounts already accrued, will not have a material adverse effect on the Company's financial condition, results of operations and cash flows.

Coldwater Creek, Saint Louis County, Missouri. The Company is one of several companies named as defendants in five tort complaints (McClurg, et al. v. MI Holdings, Inc., et al., filed February 28, 2012; Adams, et al. v. MI Holdings, Inc., et al., filed April 10, 2012, Steinmann et al. v. MI Holdings, Inc., et al., filed October 23, 2012, Schneider, et al. v. MI Holdings, Inc., et al., filed April 19, 2013 and Vorce v. MI Holdings, Inc., et al., filed June 18, 2013) with numerous plaintiffs pending in the U.S. District Court for the Eastern District of Missouri. These cases allege personal injury for alleged exposure to radiological substances present in Coldwater Creek in Missouri. Plaintiffs lived in various locations in Saint Louis County, Missouri near Coldwater Creek. Radiological residues which may have been present in the creek have been remediated by the U.S. Army Corps of Engineers. The Company believes that it has meritorious defenses to these complaints and is vigorously defending against them. The Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding the plaintiffs and their medical conditions; and (iii) there are significant factual issues to be resolved. While it is not possible at this time to determine with certainty the ultimate outcome of these cases, the Company believes that the final resolution of all known claims will not have a material adverse effect on the Company's financial condition, results of operations and cash flows.

Products Liability Litigation

The Company is one of four manufacturers of Gadolinium-Based Contrast Agents, such as the Company's Optimark™ product, involved in litigation alleging that administration of these agents causes development of nephrogenic systemic fibrosis in a small number of patients with advanced renal impairment. In May 2013, the Company agreed to terms of settlement with the plaintiffs in all of its previously disclosed lawsuits involving its Optimark™ product. These settlements resolved cases that were included in federal multi-district litigation pending in the U.S. District Court for the Northern District of Ohio (In re Gadolinium-Based Contrast Agents Product Liability Litigation, which was established on February 27, 2008) and cases in various state courts. These settlements did not have a material impact on the Company's unaudited condensed consolidated and combined financial statements.

Beginning with lawsuits brought in July 1976, the Company is also named as a defendant in personal injury lawsuits based on alleged exposure to asbestos-containing materials. A majority of the cases involve product liability claims based principally on allegations of past distribution of products containing asbestos. A limited number of the cases allege premises liability based on claims that individuals were exposed to asbestos while on the Company's property. Each case typically names dozens of corporate defendants in addition to the Company. The complaints generally seek monetary damages for personal injury or bodily injury resulting from alleged exposure to products containing asbestos. The Company's involvement in asbestos cases has been limited because it did not mine or produce asbestos. Furthermore, in the Company's experience, a large percentage of these claims have never been substantiated and have been dismissed by the courts. The Company has not suffered an adverse verdict in a trial court proceeding related to asbestos claims and intends to continue to defend these lawsuits. When appropriate, the Company settles claims; however, amounts paid to settle and defend all asbestos claims have been immaterial. As of June 28, 2013, there were approximately 11,500 asbestos-related cases pending against the Company.

The Company estimates pending asbestos claims and claims that were incurred but not reported, as well as insurance recoveries. The Company's estimate of its liability for pending and future claims is based on claims experience over the past five years and covers claims either currently filed or expected to be filed over the next seven years. The Company believes that it has adequate amounts recorded related to these matters. While it is not possible at this time to determine with certainty the ultimate outcome of these asbestos-related proceedings, the Company believes that the final outcome of all known and anticipated future claims, after taking into account amounts already accrued and insurance coverage, will not have a material adverse effect on the Company's financial condition, results of operations and cash flows.

Asset Retirement Obligations

The Company has recorded asset retirement obligations for the estimated future costs primarily associated with legal obligations to decommission facilities within the Global Medical Imaging segment, including the facilities located in the Netherlands and Maryland Heights, Missouri. Substantially all of these obligations are included in other liabilities on the unaudited condensed consolidated and combined balance sheets. The following table provides a summary of the changes in the Company's asset retirement obligations:




Balance at September 28, 2012	$	46.4
Accretion expense	2.4
Payments	(0.2		)
Currency translation	0.2
Balance at June 28, 2013	$	48.8

The Company believes that any potential payment of such estimated amounts will not have a material adverse effect on the Company's financial condition, results of operations and cash flows.

Tax Matters

The income tax returns of the Company and its subsidiaries are periodically examined by various tax authorities. The resolution of these matters is subject to the conditions set forth in the Tax Matters Agreement between the Company and Covidien. Covidien has the right to administer, control and settle all U.S. income tax audits for periods prior to the Separation. While it is not possible at this time to determine with certainty the ultimate outcome of these matters, the Company believes that established liabilities are reasonable and that final resolution of these matters will not have a material adverse effect on the Company's financial condition, results of operations and cash flows.

With respect to certain tax returns filed by predecessor affiliates of the Company and Covidien, the U.S. Internal Revenue Service ("the IRS") has concluded its field examination for the years 1997 through 2000 and has proposed tax adjustments. Several of the proposed adjustments could also affect both Covidien's and the Company's income tax returns for years after 2000. Certain of the IRS's proposed adjustments have been appealed, and all but one of the matters associated with the proposed tax adjustments have been resolved. The unresolved proposed adjustment asserts that substantially all of the predecessor affiliates' intercompany debt originating during the years 1997 through 2000 should not be treated as debt for U.S. federal income tax purposes, and has disallowed interest deductions related to the intercompany debt and certain tax attribute adjustments recognized on the U.S. income tax returns. This matter is subject to the Company's $200 million limitation for periods prior to September 29, 2012, as prescribed in the Tax Matters Agreement. While it is not possible at this time to determine with certainty the ultimate outcome of this matter, the Company believes that it will not have a material adverse effect on the Company's financial condition, results of operations and cash flows.

Other Matters

The Company is a defendant in a number of other pending legal proceedings relating to present and former operations, acquisitions and dispositions. The Company does not expect the outcome of these proceedings, either individually or in the aggregate, to have a material adverse effect on the Company's financial condition, results of operations and cash flows.

Derivative Instruments

9 Months Ended

Jun. 28, 2013

Summary of Derivative Instruments [Abstract]

Derivative Instruments



14.	Derivative Instruments

The Company is exposed to certain risks relating to its business operations. Prior to the Separation on June 28, 2013, the Company participated in the centralized hedging functions of Covidien to help mitigate risks related to foreign exchange exposure and certain commodity price exposures. Foreign currency option and forward contracts are used to manage the foreign exchange exposures of operations outside the U.S. Swap contracts on commodities were periodically entered into to manage the price risk associated with forecasted purchases of commodities used in the Company's manufacturing processes. The associated derivative assets and liabilities for these types of instruments were not included on the Company's unaudited condensed combined balance sheet prior to June 28, 2013, since derivative activity was centrally managed by Covidien. In conjunction with the Separation, the Company assumed the foreign currency option and forward contacts directly related to its business and, as such, has recognized the fair value of the these derivatives in its unaudited condensed consolidated balance sheet as of June 28, 2013. The commodity swap contracts were retained by Covidien. Changes in the fair value of the derivative financial instruments which related to the Company's business operations have been recognized in the Company's earnings unless specific hedge criteria are met. Covidien designated certain commodity swap contracts as cash flow hedges but did not designate the foreign currency forward and option contracts as hedging instruments.

Risks that relate to interest rate exposure are managed by using derivative instruments. In March 2013 and April 2013, MIFSA entered into forward interest rate lock contracts to hedge the risk of variability in the market interest rates prior to the issuance of the Notes in April 2013. These transactions have been reflected in the unaudited condensed consolidated and combined financial statements for all periods, since the transactions were solely entered into in connection with the Separation and were not centrally managed by Covidien.

Foreign Exchange Exposure

The Company has foreign exchange exposure on the translation of the financial statements and on transactions denominated in foreign currencies. Covidien's policy was to use various forward and option contracts to manage foreign currency exposures on accounts and notes receivable, accounts payable, intercompany loans and forecasted transactions that are denominated in certain foreign currencies. These contracts did not meet the necessary criteria to qualify for hedge accounting; accordingly, all associated changes in fair value were recognized in earnings. The Company assumed these outstanding forward and option contracts, and the related assets and liabilities, as a part of the Separation.

The location and amount of the net gain (loss) on foreign exchange forward and option contracts not designated as hedging instruments were recorded as follows:



	Three Months Ended						Nine Months Ended
	June 28, 2013			June 29, 2012			June 28, 2013		June 29, 2012
Cost of sales	$	1.2		$	(1.3	)	$	1.7	$	(0.1	)
Selling, general and administrative	(0.1		)	0.7			—		(0.1		)
	$	1.1		$	(0.6	)	$	1.7	$	(0.2	)

The fair value of foreign exchange forward and option contracts are included in the following captions of our unaudited condensed consolidated and combined balance sheets at the end of each period:



	June 28, 2013		September 28, 2012
Prepaid expenses and other current assets	$	1.7	$	—
Accrued and other current liabilities	3.8		—

Commodities Exposure

Prior to the Separation, Covidien entered into gas commodity swap contracts on behalf of the Company, which were accounted for as cash flow hedges. The amounts of the net losses on these contracts were recorded as follows:



	Three Months Ended				Nine Months Ended
	June 28, 2013		June 29, 2012		June 28, 2013		June 29, 2012
Cost of sales	$	0.1	$	0.3	$	0.3	$	0.8
Selling, general and administrative	0.2		0.6		0.8		2.0
	$	0.3	$	0.9	$	1.1	$	2.8

As of June 28, 2013, there were no outstanding gas commodity swap contracts; however, the Company may utilize such contracts in the future to mitigate price risk associated with its forecasted commodity purchases.

Interest Rate Exposure

MIFSA entered into three forward interest rate lock contracts in March 2013 and April 2013, each with a $300 million notional value and designated as cash flow hedges, against the risk of variability in market interest rates in advance of its anticipated issuance of its ten-year fixed rate senior notes due April 2023. Each interest rate lock contract was considered to be highly effective and the $7.6 million loss resulting from their settlements was recorded in accumulated other comprehensive income. As of June 28, 2013, $7.4 million of this loss remains in accumulated other comprehensive income and will be amortized to interest expense over the remaining term of the ten-year notes.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41635-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5580258-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624181-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41638-113959

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Financial Instruments and Fair Value Measurements

9 Months Ended

Jun. 28, 2013

Fair Value Disclosures [Abstract]

Financial Instruments and Fair Value Measurements



15.	Financial Instruments and Fair Value Measurements

Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes a three-level fair value hierarchy, which maximizes the use of observable inputs and minimizes the use of unobservable inputs used in measuring fair value. The levels within the hierarchy are as follows:

Level 1— observable inputs such as quoted prices in active markets for identical assets or liabilities;

Level 2— significant other observable inputs that are observable either directly or indirectly; and

Level 3— significant unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions.

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:



	June 28, 2013		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.6	$	22.2	$	13.4	$	—
Foreign exchange forward and option contracts	1.7		1.7		—		—
	$	37.3	$	23.9	$	13.4	$	—

Liabilities:
Deferred compensation liabilities	$	12.7	$	—	$	12.7	$	—
Contingent consideration	6.9		—		—		6.9
Foreign exchange forward and option contracts	3.8		3.8		—		—
	$	23.4	$	3.8	$	12.7	$	6.9



	September 28, 2012		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	25.2	$	13.7	$	11.5	$	—

Liabilities:
Deferred compensation liabilities	$	9.3	$	—	$	9.3	$	—

Debt and equity securities held in rabbi trust. Debt securities held in the rabbi trust primarily consist of U.S. government and agency securities and corporate bonds. When quoted prices are available in an active market, the investments are classified as level 1. When quoted market prices for a security are not available in an active market, they are classified as level 2. Equity securities held in the rabbi trust primarily consist of U.S. common stocks, which are valued using quoted market prices reported on nationally recognized securities exchanges. The $10.4 million increase in debt and equity securities held in rabbi trust primarily reflects the transfer of these assets from Covidien in connection with the Separation.

Foreign exchange forward and option contracts. Foreign currency option and forward contracts are used to economically manage the foreign exchange exposures of operations outside the U.S. Quoted prices are available in an active market; as such, these derivatives are classified as level 1.

Deferred compensation liabilities. Covidien maintains a non-qualified deferred compensation plan in the U.S., which permits eligible employees of the Company to defer a portion of their compensation. A recordkeeping account is set up for each participant and the participant chooses from a variety of funds for the deemed investment of their accounts. The measurement funds generally correspond to the funds offered in Covidien's U.S. tax-qualified defined contribution retirement plan and the account balance fluctuates with the investment returns on those funds.

Contingent consideration. In October 2012, the Company recorded contingent consideration of $6.9 million upon the acquisition of CNS Therapeutics. This contingent consideration, which could potentially total a maximum of $9.0 million, is primarily based on whether the FDA approves another dosage form of GABLOFEN® on or before December 31, 2016. The fair value of the contingent payments was measured based on the probability-weighted present value of the consideration expected to be transferred using a discount rate of 1.0%.



Balance at September 28, 2012	$	—
Acquisition date fair value of contingent consideration	6.9
Balance at June 28, 2013	$	6.9

Financial Instruments Not Measured at Fair Value

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and the majority of other current assets and liabilities approximate fair value because of their short-term nature. The Company classifies cash on hand and deposits in banks, including commercial paper, money market accounts and other investments it may hold from time to time, with a maturity to the Company of three months or less, as cash and cash equivalents (level 1). The fair value of restricted cash is equivalent to its carrying value of $23.9 million and $24.6 million as of June 28, 2013 and September 28, 2012, respectively (level 1), substantially all of which is included in other assets on the unaudited condensed consolidated and combined balance sheets. The Company's life insurance contracts are carried at cash surrender value, which is based on the present value of future cash flows under the terms of the contracts (level 3). Significant assumptions used in determining the cash surrender value include the amount and timing of future cash flows, interest rates and mortality charges. The fair value of these contracts approximates the carrying value of $66.5 million and $47.6 million at June 28, 2013 and September 28, 2012, respectively. These contracts are included in other assets on the unaudited condensed consolidated and combined balances sheets. The $18.9 million increase in the Company's life insurance contracts primarily reflects the transfer of these assets from Covidien in connection with the Separation.

The carrying value of the Company's note payable approximates fair value due to its short term nature. Since the quoted market prices for the Company's 7.00%, 8.00% and 9.50% debentures are not available in an active market, they are classified as level 2 for purposes of developing an estimate of fair value. The Company's 3.50% and 4.75% notes are classified as level 1, as quoted prices are available in an active market for these notes. The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period:



	June 28, 2013				September 28, 2012
	Carrying Value		Fair Value		Carrying Value		Fair Value
Note payable	$	0.1	$	0.1	$	—	$	—
3.50% notes due April 2018	299.9		291.6		—		—
4.75% notes due April 2023	598.1		573.0		—		—
7.00% debentures due December 2013	—		—		5.8		5.8
8.00% debentures due March 2023	8.0		10.2		—		—
9.50% debentures due May 2022	10.4		14.3		—		—

Concentration of Credit and Other Risks

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of accounts receivable. The Company does not require collateral from customers. A portion of the Company's accounts receivable outside the U.S. includes sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries' national economies. Deteriorating credit and economic conditions in parts of Western Europe, particularly in Spain and Italy, may continue to increase the average length of time it takes the Company to collect its accounts receivables in certain regions within these countries.

The Company routinely evaluates all government receivables for potential collection risks associated with the availability of government funding and reimbursement practices. The Company has not incurred any significant losses on government receivables; however, if the financial condition of customers or the countries' healthcare systems continue to deteriorate such that their ability to make payments is uncertain, additional allowances may be required in future periods.

The Company's accounts receivable, net of allowance for doubtful accounts, in Spain and Italy at the end of each period are as follows:



	June 28, 2013		September 28, 2012
Spain	$	5.3	$	15.0
Italy	14.1		12.5

Net sales to customers in Spain and Italy totaled $13.4 million and $14.0 million for the three months ended June 28, 2013 and June 29, 2012, respectively, and $39.7 million and $43.0 million for the nine months ended June 28, 2013 and June 29, 2012, respectively.

The following table shows net sales attributable to distributors that accounted for 10% or more of the Company's total net sales:



	Three Months Ended				Nine Months Ended
	June 28, 2013		June 29, 2012		June 28, 2013		June 29, 2012
Cardinal Health, Inc.	16	%	18	%	19	%	18	%
McKesson Corporation	7	%	8	%	13	%	11	%
Amerisource Bergen Corporation	10	%	6	%	8	%	7	%

The following table shows accounts receivable attributable to distributors that accounted for 10% or more of the Company's gross accounts receivable at the end of each period:



	June 28, 2013		September 28, 2012
Cardinal Health, Inc.	19	%	19	%
McKesson Corporation	18	%	20	%
Amerisource Bergen Corporation	14	%	10	%

The following table shows net sales attributable to products that accounted for 10% or more of the Company's total net sales:



	Three Months Ended				Nine Months Ended
	June 28, 2013		June 29, 2012		June 28, 2013		June 29, 2012
Optiray™ (CMDS)	16	%	17	%	15	%	17	%
Acetaminophen products (API)	11	%	11	%	10	%	11	%
Ultra-Technekow™ DTE (Nuclear Imaging)	8	%	10	%	9	%	10	%

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Income Taxes

9 Months Ended

Jun. 28, 2013

Income Tax Disclosure [Abstract]

Income Taxes



16.	Income Taxes

Income Tax Provision

Income tax expense was $19.8 million on loss from continuing operations before income taxes of $7.9 million for the three months ended June 28, 2013 and $24.4 million on income from continuing operations before income taxes of $59.5 million for the three months ended June 29, 2012. Income tax expense was $55.9 million and $73.8 million on income from continuing operations before income taxes of $82.5 million and $187.8 million for the nine months ended June 28, 2013 and June 29, 2012, respectively. This resulted in effective tax rates of a negative 250.6% and 41.0% for the three months ended June 28, 2013 and June 29, 2012, respectively, and effective tax rates of 67.8% and 39.3% for the nine months ended June 28, 2013 and June 29, 2012, respectively. Our effective tax rate for the three and nine months ended June 28, 2013 was impacted by the inability to deduct a substantial portion of our separation costs due to the tax-free status of the Separation.

Impacts of the Separation

As a result of the Separation, and pursuant to the Separation and Distribution Agreement and other agreements entered into by Covidien and Mallinckrodt, certain assets and liabilities that were formerly associated with the Pharmaceuticals business of Covidien were retained by Covidien and, conversely, certain non-operating assets and liabilities were transferred to the Company. These transfers had an impact on the tax accounts of the Company, which is described below.

At September 28, 2012, the Company's unrecognized tax benefits, excluding interest, totaled $165.5 million, $13.4 million of which was recorded as liabilities within the unaudited condensed combined balance sheet, with the remainder in parent company investment. The amounts recorded within parent company investment were retained by Covidien in connection with the Separation. The amounts recorded as liabilities within the unaudited condensed consolidated balance sheet increased to $97.6 million at June 28, 2013, due to $84.2 million being transferred to the Company from Covidien in connection with the Separation. Included within the $97.6 million of total unrecognized tax benefits at June 28, 2013, there are $93.8 million of unrecognized tax benefits, which if favorably settled would benefit the effective tax rate.

Accrued interest related to these unrecognized tax benefits was $33.9 million at September 28, 2012, with $7.9 million recorded as liabilities within the unaudited condensed combined balance sheet and the remainder in parent company investment. The amounts recorded within parent company investment were retained by Covidien in connection with the Separation. The amounts recorded as liabilities within the unaudited condensed consolidated balance sheet increased to $59.7 million at June 28, 2013, primarily due to $51.8 million being transferred to the Company from Covidien in connection with the Separation.

Amounts related to unrecognized tax benefits, including interest, along with items unrelated to unrecognized tax benefits, included within current income tax payable are $29.8 million as of June 28, 2013.

The Company's net current deferred tax asset increased from $119.9 million at September 28, 2012 to $140.6 million at June 28, 2013 due to $15.8 million being transferred to the Company from Covidien in connection with the Separation. Additionally, the Company's net noncurrent deferred tax liability increased from $73.7 million at September 28, 2012 to $241.1 million at June 28, 2013 due to $126.8 million being transferred to the Company from Covidien in connection with the Separation and $27.1 million related to the acquisition of CNS Therapeutics.

Segment Data

9 Months Ended

Jun. 28, 2013

Segment Reporting [Abstract]

Segment Data



17.	Segment Data

Selected information by business segment is as follows:



	Three Months Ended						Nine Months Ended
	June 28, 2013			June 29, 2012			June 28, 2013			June 29, 2012
Net sales:
Specialty Pharmaceuticals	$	308.6		$	254.7		$	913.2		$	746.3
Global Medical Imaging	247.9			246.7			706.7			754.0
Net sales of operating segments (1)	556.5			501.4			1,619.9			1,500.3
Net sales to related parties (2)	13.5			14.9			39.4			42.8
Net sales	$	570.0		$	516.3		$	1,659.3		$	1,543.1
Operating income (loss):
Specialty Pharmaceuticals	$	94.8		$	50.9		$	234.8		$	128.3
Global Medical Imaging	13.5			49.3			81.5			160.7
Segment operating income	108.3			100.2			316.3			289.0
Unallocated amounts:
Corporate and allocated expenses (3)	(43.7		)	(20.4		)	(109.4		)	(47.0		)
Intangible asset amortization	(8.9		)	(6.8		)	(26.6		)	(20.3		)
Restructuring and related charges, net (4)	(12.1		)	(6.4		)	(20.0		)	(17.3		)
Separation costs	(44.2		)	(7.2		)	(70.6		)	(17.4		)
Operating income (loss)	$	(0.6	)	$	59.4		$	89.7		$	187.0


(1)	Amounts represent sales to external customers. There were no intersegment sales.


(2)	Represents products that were sold to Covidien, which is discussed in note 11.


(3)	Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.


(4)	Includes restructuring-related accelerated depreciation of $0.8 million and $1.4 million for the three months ended June 28, 2013 and June 29, 2012, respectively, and $2.1 million and $6.8 million for the nine months ended June 28, 2013 and June 29, 2012, respectively.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Subsequent Events

9 Months Ended

Jun. 28, 2013

Subsequent Events [Abstract]

Subsequent Events



18.	Subsequent Events

Equity Grants

On July 1, 2013 the Compensation and Human Resources and Compensation Committee of the board of directors approved grants of initial equity awards to certain of the Company's executives. A total of 141,757 restricted share units and share options for 406,169 shares were granted. The majority of the restricted share units and the share options will vest in two equal installments on each of July 1, 2016 and July 1, 2017. The restricted share units awarded to the Company's chief executive officer, Mark Trudeau, will vest in their entirety on July 1, 2018. Total fair value of these grants approximates $12.5 million, which will be recognized over the respective employee service period.

Acquisitions (Tables)

9 Months Ended

Jun. 28, 2013

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following amounts represent the final allocation of the fair value of the identifiable assets acquired and liabilities assumed:



Current assets ⁽¹⁾	$	13.3
Intangible assets	91.9
Goodwill (non-tax deductible) ⁽²⁾	24.5
Total assets acquired	129.7
Current liabilities	4.0
Deferred tax liabilities (non-current)	27.1
Contingent consideration (non-current)	6.9
Total liabilities assumed	38.0
Net assets acquired	$	91.7


(1)	This amount includes $3.3 million of accounts receivable, which is also the gross contractual value. As of the acquisition date, the fair value of accounts receivable approximated carrying value.


(2)	Goodwill relates to the Company's ability to exploit CNS Therapeutics' technologies.

Schedule of Reconciliation of Total Consideration

The following reconciles the total consideration to net assets acquired:



Total consideration	$	95.0
Plus cash assumed in acquisition	3.6
Less: contingent consideration	(6.9		)
Net assets acquired	$	91.7

Schedule of Intangible Assets Acquired as Part of Business Combination

Intangible assets acquired consist of the following:



	Amount		Weighted-Average Amortization Period
Completed technology	$	73.1	13 years
Trademark	0.2		3 years
In-process research and development	18.6		Non-Amortizable
	$	91.9

Restructuring and Related Charges, Net (Tables)

9 Months Ended

Jun. 28, 2013

Restructuring Charges [Abstract]

Restructuring and Related Charges by Segment

Net restructuring and related charges by segment are as follows:



	Three Months Ended						Nine Months Ended
	June 28, 2013			June 29, 2012			June 28, 2013			June 29, 2012
Specialty Pharmaceuticals	$	7.0		$	2.3		$	13.6		$	10.2
Global Medical Imaging	5.1			4.1			6.4			7.1
Restructuring and related charges, net	12.1			6.4			20.0			17.3
Less: accelerated depreciation	(0.8		)	(1.4		)	(2.1		)	(6.8		)
Restructuring charges, net	$	11.3		$	5.0		$	17.9		$	10.5

Restructuring and Related Charges, Net

Net restructuring and related charges are comprised of the following:



	Three Months Ended						Nine Months Ended
	June 28, 2013			June 29, 2012			June 28, 2013			June 29, 2012
2011 Covidien program	$	11.6		$	6.3		$	18.8		$	17.1
2009 Covidien program	0.2			0.1			0.1			0.2
Acquisitions	0.3			—			1.1			—
Total programs	12.1			6.4			20.0			17.3
Less: non-cash charges, including accelerated depreciation	(0.7		)	(1.5		)	(2.1		)	(6.9		)
Total charges expected to be settled in cash	$	11.4		$	4.9		$	17.9		$	10.4

Schedule of Restructuring Reserves by Type of Cost

The following table summarizes cash activity for restructuring reserves, substantially all of which relates to employee severance and benefits under the 2011 Covidien program:




Balance at September 28, 2012	$	8.9
Charges	20.0
Changes in estimate	(2.1		)
Cash payments	(9.7		)
Reclassifications ⁽¹⁾	(1.0		)
Balance at June 28, 2013	$	16.1


(1)	Represents the reclassification of pension and other postretirement benefits from restructuring reserves to pension and postretirement obligations, and the transfer of certain restructuring liabilities in conjunction with the Separation.

Schedule of Restructuring Charges Incurred Cumulative to Date

Net restructuring and related charges, including associated asset impairments, incurred cumulative to date related to the 2011 Covidien program are as follows:




Specialty Pharmaceuticals	$	29.7
Global Medical Imaging	20.0
	$	49.7

Inventories (Tables)

9 Months Ended

Jun. 28, 2013

Inventory, Net [Abstract]

Schedule of Inventories

Inventories are comprised of the following at the end of each period:



	June 28, 2013		September 28, 2012
Raw materials and supplies	$	67.8	$	74.1
Work in process	188.9		184.7
Finished goods	166.4		176.5
Inventories	$	423.1	$	435.3

Goodwill and Intangible Assets (Tables)

9 Months Ended

Jun. 28, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The changes in the carrying amount of goodwill by segment were as follows:



	Specialty Pharmaceuticals		Global Medical Imaging		Total
Goodwill at September 28, 2012	$	287.8	$	219.7	$	507.5
Acquisitions	24.5		—		24.5
Goodwill at June 28, 2013	$	312.3	$	219.7	$	532.0

Schedule of Intangible Assets

The gross carrying amount and accumulated amortization of intangible assets at the end of each period were as follows:



	June 28, 2013				September 28, 2012
	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Amortizable:
Completed technology	$	449.2	$	190.9	$	376.1	$	173.7
Licenses	191.1		76.3		191.1		67.1
Trademarks	7.9		3.7		7.7		3.5
Total	$	648.2	$	270.9	$	574.9	$	244.3
Non-Amortizable:
Trademarks	$	35.0			$	35.0
In-process research and development	18.6				—
Total	$	53.6			$	35.0

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

The estimated aggregate amortization expense on intangible assets owned by the Company is expected to be as follows:




Remainder of fiscal 2013	$	8.8
Fiscal 2014	35.4
Fiscal 2015	35.4
Fiscal 2016	35.3
Fiscal 2017	33.9

Property, Plant and Equipment (Tables)

9 Months Ended

Jun. 28, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

The gross carrying amount and accumulated depreciation of property, plant and equipment at the end of each period was as follows:



	June 28, 2013			September 28, 2012
Property, plant and equipment, gross	$	1,826.5		$	1,751.4
Less: accumulated depreciation	(848.6		)	(806.2		)
Property, plant and equipment, net	$	977.9		$	945.2

Debt (Tables)

9 Months Ended

Jun. 28, 2013

Debt Disclosure [Abstract]

Schedule of Long-term Debt including Capital Lease Obligation

Debt was comprised of the following at the end of each period:



	June 28, 2013		September 28, 2012
Current maturities of long-term debt:
Capital lease obligation	$	1.3	$	1.3
Note payable	0.1		—
Total current debt	1.4		1.3
Long-term debt:
3.50% notes due April 2018	299.9		—
4.75% notes due April 2023	598.1		—
7.00% debentures due December 2013⁽¹⁾	—		5.8
8.00% debentures due March 2023⁽²⁾	8.0		—
9.50% debentures due May 2022⁽²⁾	10.4		—
Capital lease obligation	2.1		3.1
Total long-term debt	918.5		8.9
Total debt	$	919.9	$	10.2


(1)	Under the terms of the separation and distribution agreement entered into with Covidien on June 28, 2013, the 7.00% debentures due December 2013 were retained by Covidien.


(2)	Under the terms of the separation and distribution agreement entered into with Covidien on June 28, 2013, the 8.00% and 9.50% debentures due in March 2023 and May 2022, respectively, were transferred to the Company.

Retirement Plans (Tables)

9 Months Ended

Jun. 28, 2013

Defined Benefit Pension Plans

Defined Benefit Plan Disclosure [Line Items]

Schedule of Net Periodic Benefit Cost

The net periodic benefit cost for the Company's defined benefit pension plans was as follows:



	Three Months Ended						Nine Months Ended
	June 28, 2013			June 29, 2012			June 28, 2013			June 29, 2012
Service cost	$	1.2		$	1.3		$	3.6		$	3.9
Interest cost	4.6			5.4			13.7			16.1
Expected return on plan assets	(7.4		)	(6.2		)	(22.1		)	(18.5		)
Amortization of net actuarial loss	3.0			2.9			9.0			8.7
Amortization of prior service cost	0.1			0.2			0.4			0.5
Plan settlements loss	5.4			—			5.4			—
Net periodic benefit cost	$	6.9		$	3.6		$	10.0		$	10.7

Share Plans (Tables) - Post-Separation

9 Months Ended

Jun. 28, 2013

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Incentive Equity Awards Issued Upon Completion of Conversion

Mallinckrodt incentive equity awards issued upon completion of the Conversion and the related weighted-average grant date fair value is presented below:

Summary of the Status of Company's Share Option Awards upon Completion of Conversion

A summary of the status of the Company's share option awards upon completion of the Conversion on June 28, 2013 is presented below:



	Shares Options	Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at June 28, 2013	2,399,822	$	35.94	3.8	$	22.9
Exercisable at June 28, 2013	550,097	30.94		2.4	8.0

Schedule Valuation Assumptions



	Pre- Separation			Post- Separation
Expected share price volatility	26		%	32		%
Risk-free interest rate	0.99		%	0.99		%
Expected annual dividend per share	1.65		%	—
Expected life of options (in years)	3.8			3.8
Fair value per option	$	18.04		$	16.51
Share option awards	1,745,258			2,399,822

Commitment and Contingencies (Tables)

9 Months Ended

Jun. 28, 2013

Commitments and Contingencies Disclosure [Abstract]

Schedule of Changes in Asset Retirement Obligations

The following table provides a summary of the changes in the Company's asset retirement obligations:




Balance at September 28, 2012	$	46.4
Accretion expense	2.4
Payments	(0.2		)
Currency translation	0.2
Balance at June 28, 2013	$	48.8

Derivative Instruments (Tables)

9 Months Ended

Jun. 28, 2013

Summary of Derivative Instruments [Abstract]

Net Gain (Loss) on Foreign Exchange Forward and Option Contracts not Designated as Hedging Instruments

The location and amount of the net gain (loss) on foreign exchange forward and option contracts not designated as hedging instruments were recorded as follows:



	Three Months Ended						Nine Months Ended
	June 28, 2013			June 29, 2012			June 28, 2013		June 29, 2012
Cost of sales	$	1.2		$	(1.3	)	$	1.7	$	(0.1	)
Selling, general and administrative	(0.1		)	0.7			—		(0.1		)
	$	1.1		$	(0.6	)	$	1.7	$	(0.2	)

Schedule of Fair Value of Foreign Exchange Forward and Option Contracts in Consolidated Statements

The fair value of foreign exchange forward and option contracts are included in the following captions of our unaudited condensed consolidated and combined balance sheets at the end of each period:



	June 28, 2013		September 28, 2012
Prepaid expenses and other current assets	$	1.7	$	—
Accrued and other current liabilities	3.8		—

Net Loss on Gas Commodity Swap Contracts Designated as Cash Flow Hedging Instruments

The amounts of the net losses on these contracts were recorded as follows:



	Three Months Ended				Nine Months Ended
	June 28, 2013		June 29, 2012		June 28, 2013		June 29, 2012
Cost of sales	$	0.1	$	0.3	$	0.3	$	0.8
Selling, general and administrative	0.2		0.6		0.8		2.0
	$	0.3	$	0.9	$	1.1	$	2.8

Financial Instruments and Fair Value Measurements (Tables)

9 Months Ended

Jun. 28, 2013

Fair Value Disclosures [Abstract]

Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:



	June 28, 2013		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.6	$	22.2	$	13.4	$	—
Foreign exchange forward and option contracts	1.7		1.7		—		—
	$	37.3	$	23.9	$	13.4	$	—

Liabilities:
Deferred compensation liabilities	$	12.7	$	—	$	12.7	$	—
Contingent consideration	6.9		—		—		6.9
Foreign exchange forward and option contracts	3.8		3.8		—		—
	$	23.4	$	3.8	$	12.7	$	6.9



	September 28, 2012		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	25.2	$	13.7	$	11.5	$	—

Liabilities:
Deferred compensation liabilities	$	9.3	$	—	$	9.3	$	—

Reconciliation of Changes in Fair Value of Contingent Consideration



Balance at September 28, 2012	$	—
Acquisition date fair value of contingent consideration	6.9
Balance at June 28, 2013	$	6.9

Carrying Amount and Estimated Fair Value of Long-term Debt

The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period:



	June 28, 2013				September 28, 2012
	Carrying Value		Fair Value		Carrying Value		Fair Value
Note payable	$	0.1	$	0.1	$	—	$	—
3.50% notes due April 2018	299.9		291.6		—		—
4.75% notes due April 2023	598.1		573.0		—		—
7.00% debentures due December 2013	—		—		5.8		5.8
8.00% debentures due March 2023	8.0		10.2		—		—
9.50% debentures due May 2022	10.4		14.3		—		—

Schedules of Concentration of Credit and Other Risks, Net Sales and Accounts Receivable

The Company's accounts receivable, net of allowance for doubtful accounts, in Spain and Italy at the end of each period are as follows:



	June 28, 2013		September 28, 2012
Spain	$	5.3	$	15.0
Italy	14.1		12.5

Schedules of Concentration of Risk

The following table shows net sales attributable to distributors that accounted for 10% or more of the Company's total net sales:



	Three Months Ended				Nine Months Ended
	June 28, 2013		June 29, 2012		June 28, 2013		June 29, 2012
Cardinal Health, Inc.	16	%	18	%	19	%	18	%
McKesson Corporation	7	%	8	%	13	%	11	%
Amerisource Bergen Corporation	10	%	6	%	8	%	7	%

The following table shows accounts receivable attributable to distributors that accounted for 10% or more of the Company's gross accounts receivable at the end of each period:



	June 28, 2013		September 28, 2012
Cardinal Health, Inc.	19	%	19	%
McKesson Corporation	18	%	20	%
Amerisource Bergen Corporation	14	%	10	%

The following table shows net sales attributable to products that accounted for 10% or more of the Company's total net sales:



	Three Months Ended				Nine Months Ended
	June 28, 2013		June 29, 2012		June 28, 2013		June 29, 2012
Optiray™ (CMDS)	16	%	17	%	15	%	17	%
Acetaminophen products (API)	11	%	11	%	10	%	11	%
Ultra-Technekow™ DTE (Nuclear Imaging)	8	%	10	%	9	%	10	%

- Definition

Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.

+ References + Details

Segment Data (Tables)

9 Months Ended

Jun. 28, 2013

Segment Reporting [Abstract]

Schedule of Segment Reporting Information by Business Segment



17.	Segment Data

Selected information by business segment is as follows:



	Three Months Ended						Nine Months Ended
	June 28, 2013			June 29, 2012			June 28, 2013			June 29, 2012
Net sales:
Specialty Pharmaceuticals	$	308.6		$	254.7		$	913.2		$	746.3
Global Medical Imaging	247.9			246.7			706.7			754.0
Net sales of operating segments (1)	556.5			501.4			1,619.9			1,500.3
Net sales to related parties (2)	13.5			14.9			39.4			42.8
Net sales	$	570.0		$	516.3		$	1,659.3		$	1,543.1
Operating income (loss):
Specialty Pharmaceuticals	$	94.8		$	50.9		$	234.8		$	128.3
Global Medical Imaging	13.5			49.3			81.5			160.7
Segment operating income	108.3			100.2			316.3			289.0
Unallocated amounts:
Corporate and allocated expenses (3)	(43.7		)	(20.4		)	(109.4		)	(47.0		)
Intangible asset amortization	(8.9		)	(6.8		)	(26.6		)	(20.3		)
Restructuring and related charges, net (4)	(12.1		)	(6.4		)	(20.0		)	(17.3		)
Separation costs	(44.2		)	(7.2		)	(70.6		)	(17.4		)
Operating income (loss)	$	(0.6	)	$	59.4		$	89.7		$	187.0


(1)	Amounts represent sales to external customers. There were no intersegment sales.


(2)	Represents products that were sold to Covidien, which is discussed in note 11.


(3)	Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.


(4)	Includes restructuring-related accelerated depreciation of $0.8 million and $1.4 million for the three months ended June 28, 2013 and June 29, 2012, respectively, and $2.1 million and $6.8 million for the nine months ended June 28, 2013 and June 29, 2012, respectively.

Background and Basis of Presentation Background and Basis of Presentation (Details) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Jun. 28, 2013 USD ($) Country $ / shares shares	Jun. 29, 2012 USD ($)	Jun. 28, 2013 USD ($) Country $ / shares shares	Jun. 29, 2012 USD ($)	Sep. 28, 2012 $ / shares shares
Schedule of Basis of Presenation [Line Items]
Number of countries in which entity has sales presence \| Country	50		50
Distribution ratio	0.125		0.125
Stock issued	57,694,885		57,694,885
Ordinary shares, par value (in usd per share) \| $ / shares	$ 0.20		$ 0.20		$ 0
Preferred shares, authorized (in shares)	500,000,000		500,000,000		0
Preferred shares, par value (in usd per share) \| $ / shares	$ 0.20		$ 0.20		$ 0
Preferred shares, issued (in shares)	0		0		0
Preferred shares, outstanding (in shares)	0		0
Covidien PLC \| Selling, general and administrative
Schedule of Basis of Presenation [Line Items]
Allocated expenses \| $	$ 14.1	$ 13.1	$ 39.6	$ 35.8

Acquisitions (Narrative) (Details) - USD ($) $ in Millions		3 Months Ended	9 Months Ended
Acquisitions (Narrative) (Details) - USD ($) $ in Millions	Oct. 01, 2012	Jun. 28, 2013	Jun. 28, 2013	Jun. 29, 2012
Business Acquisition [Line Items]
Cash payment, net of cash acquired			$ 88.1	$ 0.0
Assumptions used calculating in-process research and development, discount rate	35.00%
CNS Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Total consideration	$ 95.0
Cash payment, net of cash acquired	88.1
Cash acquired	3.6
Contingent consideration	6.9
Contingent consideration, potential maximum	9.0
Net sales		$ 7.5	$ 20.8
In-process research and development [Member]
Business Acquisition [Line Items]
Estimated cost to complete in-process research	$ 18.0

Acquisitions (Schedule of Fair Value of Identifiable Assets Acquired and Liabilities Assumed) (Details) - USD ($)
$ in Millions

Oct. 01, 2012

Jun. 28, 2013

Sep. 28, 2012

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]

Goodwill (non-tax deductible)

$ 532.0

$ 507.5

CNS Therapeutics, Inc. [Member]

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]

Current assets

^[1]

$ 13.3

Intangible assets

91.9

Goodwill (non-tax deductible)

24.5

Total assets acquired

129.7

Current liabilities

4.0

Deferred tax liabilities (non-current)

27.1

Contingent consideration (non-current)

6.9

Total liabilities assumed

38.0

Net assets acquired

91.7

Account receivable

3.3

Total consideration

95.0

Plus cash assumed in acquisition

3.6

Less: contingent consideration

(6.9)

Net assets acquired

$ 91.7

[1]	This amount includes $3.3 million of accounts receivable, which is also the gross contractual value. As of the acquisition date, the fair value of accounts receivable approximated carrying value.

Acquisitions (Schedule of Intangible Assets Acquired) (Details) $ in Millions	Oct. 01, 2012 USD ($)
Completed technology [Member]
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life	13 years
Trademarks [Member]
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets acquired, weighted-average useful life	3 years
CNS Therapeutics, Inc. [Member]
Intangible Assets Acquired as Part of Business Combination [Line Items]
Intangible assets	$ 91.9
CNS Therapeutics, Inc. [Member] \| In-process research and development [Member]
Intangible Assets Acquired as Part of Business Combination [Line Items]
Indefinite lived intangible assets acquired	18.6
CNS Therapeutics, Inc. [Member] \| Completed technology [Member]
Intangible Assets Acquired as Part of Business Combination [Line Items]
Amortizable intangible assets acquired	73.1
CNS Therapeutics, Inc. [Member] \| Trademarks [Member]
Intangible Assets Acquired as Part of Business Combination [Line Items]
Amortizable intangible assets acquired	$ 0.2

Restructuring and Related Charges, Net (Restructuring and Related Charges by Segment) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 28, 2013	Jun. 29, 2012	Jun. 28, 2013	Jun. 29, 2012
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges, net	$ 12.1	$ 6.4	$ 20.0	$ 17.3
Less: accelerated depreciation	(0.8)	(1.4)	(2.1)	(6.8)
Restructuring charges, net	11.3	5.0	17.9	10.5
Specialty Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges, net	7.0	2.3	13.6	10.2
Global Medical Imaging
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges, net	$ 5.1	$ 4.1	$ 6.4	$ 7.1

Restructuring and Related Charges, Net (Net Restructuring and Related Charges by Program) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 28, 2013	Jun. 29, 2012	Jun. 28, 2013	Jun. 29, 2012
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges, net	$ 12.1	$ 6.4	$ 20.0	$ 17.3
Less: non-cash charges, including accelerated depreciation	(0.7)	(1.5)	(2.1)	(6.9)
Total charges expected to be settled in cash	11.4	4.9	17.9	10.4
2011 Covidien program
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges, net	11.6	6.3	18.8	17.1
2009 Covidien program
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges, net	0.2	0.1	0.1	0.2
Acquisitions
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges, net	$ 0.3	$ 0.0	$ 1.1	$ 0.0

Restructuring and Related Charges, Net (Restructuring Reserves) (Details) - USD ($)
$ in Millions

3 Months Ended

9 Months Ended

Jun. 28, 2013

Jun. 29, 2012

Jun. 28, 2013

Jun. 29, 2012

Restructuring Reserve [Roll Forward]

Charges

$ 11.3

$ 5.0

$ 17.9

$ 10.5

2011 Covidien program

Restructuring Reserve [Roll Forward]

8.9

20.0

(2.1)

(9.7)

^[1]

(1.0)

Ending Balance

$ 16.1

[1]	Represents the reclassification of pension and other postretirement benefits from restructuring reserves to pension and postretirement obligations, and the transfer of certain restructuring liabilities in conjunction with the Separation.

Restructuring and Related Charges, Net (2011 Covidien Program) (Details) - 2011 Covidien program $ in Millions	33 Months Ended
	Jun. 28, 2013 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	$ 49.7
Specialty Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	29.7
Global Medical Imaging
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	$ 20.0

Earnings (loss) per Share (Details)	Jun. 28, 2013
Earnings Per Share [Abstract]
Distribution ratio	0.125

Inventories (Details) - USD ($) $ in Millions	Jun. 28, 2013	Sep. 28, 2012
Inventory, Net [Abstract]
Raw materials and supplies	$ 67.8	$ 74.1
Work in process	188.9	184.7
Finished goods	166.4	176.5
Inventories	$ 423.1	$ 435.3

Goodwill and Intangible Assets (Schedule Of Goodwill) (Details) $ in Millions	9 Months Ended
	Jun. 28, 2013 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 507.5
Acquisitions	24.5
Ending balance	532.0
Specialty Pharmaceuticals
Goodwill [Roll Forward]
Beginning balance	287.8
Acquisitions	24.5
Ending balance	312.3
Global Medical Imaging
Goodwill [Roll Forward]
Beginning balance	219.7
Acquisitions	0.0
Ending balance	$ 219.7

Goodwill and Intangible Assets (Schedule Of Intangible Assets) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 28, 2013	Jun. 29, 2012	Jun. 28, 2013	Jun. 29, 2012	Sep. 28, 2012
Schedule of Intangible Asset by Major Class [Line Items]
Gross Carrying Amount, Amortizable	$ 648.2		$ 648.2		$ 574.9
Accumulated Amortization	270.9		270.9		244.3
Gross Carrying Amount, Non-Amortizable	53.6		53.6		35.0
Intangible asset amortization	8.9	$ 6.8	26.6	$ 20.3
Trademarks [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Gross Carrying Amount, Non-Amortizable	35.0		35.0		35.0
In-process research and development [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Gross Carrying Amount, Non-Amortizable	18.6		18.6		0.0
Completed technology [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Gross Carrying Amount, Amortizable	449.2		449.2		376.1
Accumulated Amortization	190.9		190.9		173.7
Licensing Agreements
Schedule of Intangible Asset by Major Class [Line Items]
Gross Carrying Amount, Amortizable	191.1		191.1		191.1
Accumulated Amortization	76.3		76.3		67.1
Trademarks [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Gross Carrying Amount, Amortizable	7.9		7.9		7.7
Accumulated Amortization	$ 3.7		$ 3.7		$ 3.5

Goodwill and Intangible Assets Amortization of Intangibles (Details) $ in Millions	Jun. 28, 2013 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of fiscal 2013	$ 8.8
Fiscal 2014	35.4
Fiscal 2015	35.4
Fiscal 2016	35.3
Fiscal 2017	$ 33.9

Property, Plant and Equipment (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 28, 2013	Jun. 29, 2012	Jun. 28, 2013	Jun. 29, 2012	Sep. 28, 2012
Property, Plant and Equipment [Abstract]
Property, plant and equipment, gross	$ 1,826.5		$ 1,826.5		$ 1,751.4
Less: accumulated depreciation	(848.6)		(848.6)		(806.2)
Property, plant and equipment, net	977.9		977.9		$ 945.2
Depreciation	$ 25.3	$ 24.5	$ 72.8	$ 74.5

Debt (Schedule of Long term debt and Capital lease obligation) (Details) - USD ($)
$ in Millions

Jun. 28, 2013

Sep. 28, 2012

Current maturities of long-term debt:

Capital lease obligation

$ 1.3

Total current debt

1.4

1.3

Long-term debt:

Capital lease obligation

2.1

3.1

Total long-term debt

918.5

8.9

Total debt

919.9

10.2

Senior Notes | 3.50% Senior Note

Long-term debt:

Long term debt, excluding current maturities

299.9

0.0

Senior Notes | 4.75% Senior Note

Long-term debt:

Long term debt, excluding current maturities

598.1

0.0

Debentures | 7.00% Debenture

Long-term debt:

Long term debt, excluding current maturities

^[1]

0.0

5.8

Debentures | 8.00% Debenture

Long-term debt:

Long term debt, excluding current maturities

^[2]

8.0

0.0

Debentures | 9.50% Debenture

Long-term debt:

Long term debt, excluding current maturities

^[2]

10.4

0.0

Note Payable

Current maturities of long-term debt:

Note payable

$ 0.1

$ 0.0

[1]	Under the terms of the separation and distribution agreement entered into with Covidien on June 28, 2013, the 7.00% debentures due December 2013 were retained by Covidien.
[2]	Under the terms of the separation and distribution agreement entered into with Covidien on June 28, 2013, the 8.00% and 9.50% debentures due in March 2023 and May 2022, respectively, were transferred to the Company.

Debt (Narrative) (Details) - USD ($)	1 Months Ended		3 Months Ended	9 Months Ended
Debt (Narrative) (Details) - USD ($)	Apr. 30, 2013	Mar. 31, 2013	Jun. 28, 2013	Jun. 28, 2013
Debt Instrument [Line Items]
Aggregate net proceeds	$ 889,300,000
Debentures \| 7.00% Debenture
Debt Instrument [Line Items]
Stated interest rate			7.00%	7.00%
Debentures \| 8.00% Debenture
Debt Instrument [Line Items]
Stated interest rate			8.00%	8.00%
Debentures \| 9.50% Debenture
Debt Instrument [Line Items]
Stated interest rate			9.50%	9.50%
Line of Credt
Debt Instrument [Line Items]
Facility fees for letters of credit			0.25%
Borrowings, outstanding			$ 0	$ 0
Letters of credit outstanding			$ 0.0	$ 0.0
Term of debt instrument		5 years
Maximum borrowing capacity		$ 250,000,000
Senior Notes
Debt Instrument [Line Items]
Term of debt instrument			10 years
Senior Notes \| 3.50% Senior Note
Debt Instrument [Line Items]
Face amount	$ 300,000,000
Stated interest rate	3.50%
Senior Notes \| 4.75% Senior Note
Debt Instrument [Line Items]
Face amount	$ 600,000,000
Stated interest rate	4.75%
Line of Credt \| LIBOR
Debt Instrument [Line Items]
Variable interest rate				1.50%
Letter of Credit \| Line of Credt
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 150,000,000

Retirement Plans (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Retirement Plans (Details) - USD ($) $ in Millions	Jun. 28, 2013	Jun. 29, 2012	Jun. 28, 2013	Jun. 29, 2012
Defined Benefit Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 1.2	$ 1.3	$ 3.6	$ 3.9
Interest cost	4.6	5.4	13.7	16.1
Expected return on plan assets	(7.4)	(6.2)	(22.1)	(18.5)
Amortization of net actuarial loss	3.0	2.9	9.0	8.7
Amortization of prior service cost	0.1	0.2	0.4	0.5
Plan settlements loss	5.4	0.0	5.4	0.0
Net period benefit cost (credit)	6.9	3.6	10.0	10.7
Company contributions to pension plans			37.5
Postretirement Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Net period benefit cost (credit)	$ (1.6)	$ (1.5)	$ (4.7)	$ (4.4)

Share Plans (Details) - USD ($)		3 Months Ended		9 Months Ended
Share Plans (Details) - USD ($)	Jun. 28, 2013	Jun. 28, 2013	Jun. 29, 2012	Jun. 28, 2013	Jun. 29, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation cost		$ 4,600,000	$ 2,600,000	$ 11,400,000	$ 8,300,000
Conversion of Covidien Equity Awards
Shares Options, Outstanding	2,399,822	2,399,822		2,399,822
Shares Options, Exercisable	550,097	550,097		550,097
Weighted- Average Exercise Price, Outstanding options	$ 35.94	$ 35.94		$ 35.94
Weighted- Average Exercise Price, Exercisable options	$ 30.94	$ 30.94		$ 30.94
Weighted- Average Remaining Contractual Term, Outstanding options	3 years 9 months 18 days
Weighted- Average Remaining Contractual Term, Exercisable options	2 years 4 months 24 days
Aggregate Intrinsic Value, Outstanding options	$ 22.9	$ 22.9		$ 22.9
Aggregate Intrinsic Value, Exercisable options	$ 8.0	$ 8.0		$ 8.0
Pre-Separation
Conversion of Covidien Equity Awards
Shares Options, Outstanding	1,745,258	1,745,258		1,745,258
Weighted Average Assumptions
Expected share price volatility	26.00%
Risk-free interest rate	0.99%
Expected annual dividend per share	1.65%
Expected life of options (in years)	3 years 9 months 18 days
Fair value per option	$ 18.04	$ 18.04		$ 18.04
Post-Separation
Conversion of Covidien Equity Awards
Weighted-Average Grant-Date Fair Value, Share options	$ 7.96	$ 7.96		$ 7.96
Shares Options, Outstanding	2,399,822	2,399,822		2,399,822
Weighted Average Assumptions
Expected share price volatility	32.00%
Risk-free interest rate	0.99%
Expected annual dividend per share	0.00%
Expected life of options (in years)	3 years 9 months 18 days
Fair value per option	$ 16.51	$ 16.51		$ 16.51
Restricted Share Units \| Post-Separation
Conversion of Covidien Equity Awards
Awards, Restricted share units	552,305	552,305		552,305
Weighted Average Grant Date Fair Value, Restricted share units	$ 36.09	$ 36.09		$ 36.09

Related Party Transactions (Details) - Covidien PLC - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 28, 2013	Jun. 29, 2012	Jun. 28, 2013	Jun. 29, 2012	Sep. 28, 2012
Related Party Transaction [Line Items]
Inventory purchases	$ 9.6	$ 8.1	$ 31.6	$ 25.1
Due from related parties	22.3		22.3
Due to related parties	61.9		61.9
Separation Agreement with Covidien
Related Party Transaction [Line Items]
Initial cash capitalization	168.0		168.0
Estimated cash upon completion of distribution	168.0		168.0
Adjustment payment	20.0		20.0
Tax Matters Agreement
Related Party Transaction [Line Items]
Tax agreement, tax threshold	$ 200.0		$ 200.0
Change in ownership percentage	35.00%		35.00%
Minimum \| Tax Matters Agreement
Related Party Transaction [Line Items]
Term of restriction after dividend distribution	2 years		2 years
Maximum \| Tax Matters Agreement
Related Party Transaction [Line Items]
Term of restriction after dividend distribution	5 years		5 years
Sales Revenue, Net
Related Party Transaction [Line Items]
Inventory sold	$ 13.5	14.9	$ 39.4	42.8
Selling, general and administrative
Related Party Transaction [Line Items]
Allocated expenses	$ 14.1	$ 13.1	39.6	$ 35.8
Inventories
Related Party Transaction [Line Items]
Inventory purchases			$ 8.1		$ 4.5

Guarantees (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
Guarantees (Narrative) (Details) - USD ($) $ in Millions	Jun. 28, 2013	Sep. 28, 2012
Indemnification Specialty Chemicals Business
Guarantor Obligations [Line Items]
Guarantor obligations, obligation term	17 years
Maximum future payments	$ 75.5
Escrow deposit	30.0
Indemnification Specialty Chemicals Business \| Other Assets
Guarantor Obligations [Line Items]
Guarantors obligation	22.4	$ 22.4
Escrow deposit	23.5	24.5
Maryland Heights, Missouri \| Surety Bond
Guarantor Obligations [Line Items]
Maximum future payments	58.0
St. Louis, Missouri \| Letter of Credit
Guarantor Obligations [Line Items]
Maximum future payments	21.1
St. Louis, Missouri \| Others
Guarantor Obligations [Line Items]
Maximum future payments	27.3
Enviornmental, Health and Safety Matters [Member] \| Indemnification Specialty Chemicals Business \| Other Assets
Guarantor Obligations [Line Items]
Guarantors obligation	$ 18.3	$ 18.3

Commitments and Contingencies (Details) $ in Millions	9 Months Ended
Commitments and Contingencies (Details) $ in Millions	Jun. 28, 2013 USD ($) Case Defendent	Sep. 28, 2012 USD ($)
Loss Contingencies [Line Items]
Environmental liabilities	$ 48.2
Remedial cost range, minimum	48.1
Remedial cost range, maximum	$ 85.6
Estimation of liability, historical term	5 years
Estimation of liability, expected future term of claims	7 years
Asset Retirement Obligation [Roll Forward]
Beginning Balance	$ 46.4
Accretion expense	2.4
Payments	(0.2)
Currency translation	0.2
Ending Balance	$ 48.8
Asbestos Matters
Loss Contingencies [Line Items]
Asbestos related pending cases \| Case	11,500
Accrued and other current liabilities
Loss Contingencies [Line Items]
Liability recorded for remidial costs, current	$ 9.0
Subpoena from US Attorney's Office for the Northern District of California [Member]
Loss Contingencies [Line Items]
Litigation settlement	$ 3.5
Coldwater Creek, St. Louis County, Missouri
Loss Contingencies [Line Items]
Number of cases \| Defendent	5
Products Liability Litigation
Loss Contingencies [Line Items]
Number of defendants \| Defendent	4
Covidien PLC \| Orrington Maine Environmental Matter
Loss Contingencies [Line Items]
Environmental liabilities		$ 95.8
Remedial cost range, minimum		95.8
Remedial cost range, maximum		$ 170.3
Tax Matters Agreement \| Covidien PLC
Loss Contingencies [Line Items]
Tax agreement, tax threshold	$ 200.0

Derivative Instruments (Net Gain (Loss) on Foreign Exchange Forward and Option Contracts not Designated as Hedging Instruments) (Details) - Not Designated as Hedging Instrument - Foreign Exchange Forward and Option - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 28, 2013	Jun. 29, 2012	Jun. 28, 2013	Jun. 29, 2012
Derivative Instruments, (Loss) Gain [Line Items]
Net gain (loss) on foreign exchange forward and option contracts not designated as hedging instruments	$ 1.1	$ (0.6)	$ 1.7	$ (0.2)
Cost of sales
Derivative Instruments, (Loss) Gain [Line Items]
Net gain (loss) on foreign exchange forward and option contracts not designated as hedging instruments	1.2	(1.3)	1.7	(0.1)
Selling, general and administrative
Derivative Instruments, (Loss) Gain [Line Items]
Net gain (loss) on foreign exchange forward and option contracts not designated as hedging instruments	$ (0.1)	$ 0.7	$ 0.0	$ (0.1)

Derivative Instruments (Fair Values Of Foreign Exchange Forward And Option Contracts Not Designated As Hedging Instruments Reported In The Consolidated Balance Sheets) (Details) - Foreign Exchange Forward and Option - Not Designated as Hedging Instrument - USD ($) $ in Millions	Jun. 28, 2013	Sep. 28, 2012
Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Foreign exchange forward and option contracts, asset	$ 1.7	$ 0.0
Accrued and other current liabilities
Derivatives, Fair Value [Line Items]
Foreign exchange forward and option contracts, liability	$ 3.8	$ 0.0

Derivative Instruments (Net Loss on Gas Commodity Swap Contracts Designated as Cash Flow Hedges) (Details) - Cash Fow Hedges - Designated as Hedging Instrument - Gas Commodity Swap Contract - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 28, 2013	Jun. 29, 2012	Jun. 28, 2013	Jun. 29, 2012
Derivative Instruments, Gain (Loss) [Line Items]
Net gain (loss) on commodity swap contracts	$ (0.3)	$ (0.9)	$ (1.1)	$ (2.8)
Cost of sales
Derivative Instruments, Gain (Loss) [Line Items]
Net gain (loss) on commodity swap contracts	(0.1)	(0.3)	(0.3)	(0.8)
Selling, general and administrative
Derivative Instruments, Gain (Loss) [Line Items]
Net gain (loss) on commodity swap contracts	$ (0.2)	$ (0.6)	$ (0.8)	$ (2.0)

Derivative Instruments (Narrative) (Details) $ in Millions	3 Months Ended	9 Months Ended
Derivative Instruments (Narrative) (Details) $ in Millions	Jun. 28, 2013 USD ($)	Jun. 28, 2013 USD ($)	Mar. 31, 2013 USD ($) contract
Senior Notes
Derivative Instruments, Gain (Loss) [Line Items]
Term of debt instrument	10 years
Designated as Hedging Instrument \| Forward Interest Rate Lock Contract \| Cash Fow Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Forward interest rate lock contracts, number \| contract			3
Forward interest rate lock contracts, notional amount			$ 300.0
Losses resulting from terminated derivatives, recorded in AOCI		$ 7.6
Loss included within AOCI related to terminated interest rate lock contracts	$ 7.4	$ 7.4

Financial Instruments and Fair Value Measurements (Narrative) (Details) - USD ($)
$ in Millions

3 Months Ended

9 Months Ended

Jun. 28, 2013

Jun. 29, 2012

Jun. 28, 2013

Jun. 29, 2012

Apr. 30, 2013

Oct. 01, 2012

Sep. 28, 2012

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Increase (decrease) in cash surrender value of life insurance contracts

$ 18.9

Net sales

$ 570.0

$ 516.3

1,659.3

$ 1,543.1

Spain and Italy

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Net sales

$ 13.4

$ 14.0

$ 39.7

$ 43.0

CNS Therapeutics, Inc.

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair value of contingent consideration upon acquisition

$ 6.9

Maximum contingent payments for acquisition

$ 9.0

Discount rate

1.00%

Debentures | 7.00% Debenture

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Stated interest rate

7.00%

Debentures | 7.00% Debenture | Level 2

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Stated interest rate

^[1]

7.00%

Debentures | 8.00% Debenture

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Stated interest rate

8.00%

Debentures | 8.00% Debenture | Level 2

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Stated interest rate

^[1]

8.00%

Debentures | 9.50% Debenture

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Stated interest rate

9.50%

Debentures | 9.50% Debenture | Level 2

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Stated interest rate

^[1]

9.50%

Senior Notes | 3.50% Senior Note

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Stated interest rate

3.50%

Senior Notes | 3.50% Senior Note | Level 1

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Stated interest rate

^[1]

3.50%

Senior Notes | 4.75% Senior Note

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Stated interest rate

4.75%

Senior Notes | 4.75% Senior Note | Level 1

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Stated interest rate

^[1]

4.75%

Carrying Value | Level 1

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Restricted cash and cash equivalents

$ 23.9

$ 24.6

Carrying Value | Level 3

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash surrender value of life insurance

$ 66.5

66.5

$ 47.6

Recurring | Securities

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Increase (decrease) in fair value of investments

$ 10.4

[1]	Under the terms of the separation and distribution agreement entered into with Covidien on June 28, 2013, the 7.00% debentures due December 2013 were retained by Covidien.

Financial Instruments and Fair Value Measurements (Summary of Significant Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) - Recurring - USD ($) $ in Millions	Jun. 28, 2013	Sep. 28, 2012
Total
Assets:
Debt and equity securities held in rabbi trusts	$ 35.6	$ 25.2
Foreign exchange forward and option contracts	1.7
Total assets at fair value	37.3
Liabilities:
Deferred compensation liabilities	12.7	9.3
Contingent consideration	6.9
Foreign exchange forward and option contracts	3.8
Total liabilities at fair value	23.4
Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Debt and equity securities held in rabbi trusts	22.2	13.7
Foreign exchange forward and option contracts	1.7
Total assets at fair value	23.9
Liabilities:
Deferred compensation liabilities	0.0	0.0
Contingent consideration	0.0
Foreign exchange forward and option contracts	3.8
Total liabilities at fair value	3.8
Significant Other Observable Inputs (Level 2)
Assets:
Debt and equity securities held in rabbi trusts	13.4	11.5
Foreign exchange forward and option contracts	0.0
Total assets at fair value	13.4
Liabilities:
Deferred compensation liabilities	12.7	9.3
Contingent consideration	0.0
Foreign exchange forward and option contracts	0.0
Total liabilities at fair value	12.7
Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	0.0	0.0
Foreign exchange forward and option contracts	0.0
Total assets at fair value	0.0
Liabilities:
Deferred compensation liabilities	0.0	$ 0.0
Contingent consideration	6.9
Foreign exchange forward and option contracts	0.0
Total liabilities at fair value	$ 6.9

Financial Instruments and Fair Value Measurements (Reconciliation of Changes in Fair Value) (Details) - Contingent Consideration - CNS Therapeutics, Inc. $ in Millions	9 Months Ended
	Jun. 28, 2013 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 0.0
Acquisition date fair value of contingent consideration	6.9
Ending balance	$ 6.9

Financial Instruments and Fair Value Measurements (Carrying Amount and Estimated Fair Value of Long-term Debt) (Details) - USD ($) $ in Millions	Jun. 28, 2013	Sep. 28, 2012
Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Note payable	$ 0.1	$ 0.0
Fair Value \| Senior Notes \| 3.50% Senior Note
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	291.6	0.0
Fair Value \| Senior Notes \| 4.75% Senior Note
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	573.0	0.0
Fair Value \| Debentures \| 7.00% Debenture
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	0.0	5.8
Fair Value \| Debentures \| 8.00% Debenture
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	10.2	0.0
Fair Value \| Debentures \| 9.50% Debenture
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	14.3	0.0
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Note payable	0.1	0.0
Carrying Value \| Senior Notes \| 3.50% Senior Note
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	299.9	0.0
Carrying Value \| Senior Notes \| 4.75% Senior Note
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	598.1	0.0
Carrying Value \| Debentures \| 7.00% Debenture
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	0.0	5.8
Carrying Value \| Debentures \| 8.00% Debenture
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	8.0	0.0
Carrying Value \| Debentures \| 9.50% Debenture
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	$ 10.4	$ 0.0

Financial Instruments and Fair Value Measurements (Schedule of Accounts Receivable Outstanding for Spain and Italy) (Details) - USD ($) $ in Millions	Jun. 28, 2013	Sep. 28, 2012
Spain
Segment Reporting Information [Line Items]
Accounts receivable	$ 5.3	$ 15.0
Italy
Segment Reporting Information [Line Items]
Accounts receivable	$ 14.1	$ 12.5

Financial Instruments and Fair Value Measurements (Concentration of Credit and Other Risks, Net Sales and Accounts Receivable) (Details)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 28, 2013	Jun. 29, 2012	Jun. 28, 2013	Jun. 29, 2012	Sep. 28, 2012
Net Sales Attributable to Distributors \| Cardinal Health, Inc.
Concentration Risk [Line Items]
Concentration risk, percentage	16.00%	18.00%	19.00%	18.00%
Net Sales Attributable to Distributors \| McKesson Corporation
Concentration Risk [Line Items]
Concentration risk, percentage	7.00%	8.00%	13.00%	11.00%
Net Sales Attributable to Distributors \| Amerisource Bergen Corporation
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%	6.00%	8.00%	7.00%
Accounts Receivable Attributable to Distributors \| Cardinal Health, Inc.
Concentration Risk [Line Items]
Concentration risk, percentage			19.00%		19.00%
Accounts Receivable Attributable to Distributors \| McKesson Corporation
Concentration Risk [Line Items]
Concentration risk, percentage			18.00%		20.00%
Accounts Receivable Attributable to Distributors \| Amerisource Bergen Corporation
Concentration Risk [Line Items]
Concentration risk, percentage			14.00%		10.00%
Net Sales Attributable to Products \| Optiray (CMDS)
Concentration Risk [Line Items]
Concentration risk, percentage	16.00%	17.00%	15.00%	17.00%
Net Sales Attributable to Products \| Acetaminophen products (API)
Concentration Risk [Line Items]
Concentration risk, percentage	11.00%	11.00%	10.00%	11.00%
Net Sales Attributable to Products \| Ultra-Technekow DTE (Nuclear Imaging)
Concentration Risk [Line Items]
Concentration risk, percentage	8.00%	10.00%	9.00%	10.00%

Income Taxes (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Jun. 28, 2013	Jun. 28, 2013	Jun. 29, 2012	Jun. 28, 2013	Jun. 29, 2012	Sep. 28, 2012
Operating Loss Carryforwards [Line Items]
Provision for income taxes		$ 19.8	$ 24.4	$ 55.9	$ 73.8
Income from continuing operations before income taxes		$ (7.9)	$ 59.5	$ 82.5	$ 187.8
Effective income tax rate , percent		(250.60%)	41.00%	67.80%	39.30%
Deferred income taxes	$ 140.6	$ 140.6		$ 140.6		$ 119.9
Deferred income taxes, non current	241.1	241.1		241.1		73.7
Pre-Separation
Operating Loss Carryforwards [Line Items]
Unrecognized tax benefits						165.5
Interest accrued on unrecognized tax benefits						33.9
Deferred income taxes						119.9
Deferred income taxes, non current						73.7
Pre-Separation \| Other Income Tax Liabilities
Operating Loss Carryforwards [Line Items]
Unrecognized tax benefits						13.4
Interest accrued on unrecognized tax benefits						$ 7.9
Post-Separation
Operating Loss Carryforwards [Line Items]
Unrecognized tax benefits	97.6	97.6		97.6
Unrecognized tax benefit transferred from Covidien	84.2
Unrecognized tax benefits, which if favorably settled would benefit the effective tax rate	93.8	93.8		93.8
Interest accrued on unrecognized tax benefits	59.7	59.7		59.7
Increase in accrued interest from unrecognized tax benefit on income taxes accrued due to spin-off	51.8
Unrecognized tax benefits and the accrued interest on the unrecognized tax benefits, current	29.8	29.8		29.8
Deferred income taxes	140.6	140.6		140.6
Increase in deferred income taxes due to transfer from Covidien, current	15.8
Deferred income taxes, non current	241.1	$ 241.1		241.1
Increase in deferred income taxes due to transfer from Covidien, non current	$ 126.8
Post-Separation \| CNS Therapeutics, Inc.
Operating Loss Carryforwards [Line Items]
Increase in deferred income taxes due to acquisition				$ 27.1

Segment Data (Schedule of Segment Reporting Information by Business Segment) (Details) - USD ($)

3 Months Ended

9 Months Ended

Jun. 28, 2013

Jun. 29, 2012

Jun. 28, 2013

Jun. 29, 2012

Net sales

$ 570,000,000

$ 516,300,000

$ 1,659,300,000

$ 1,543,100,000

Operating income

(600,000)

59,400,000

89,700,000

187,000,000

Intangible asset amortization

(8,900,000)

(6,800,000)

(26,600,000)

(20,300,000)

Restructuring and related charges, net

(12,100,000)

(6,400,000)

(20,000,000)

(17,300,000)

Separation costs

(44,200,000)

(7,200,000)

(70,600,000)

(17,400,000)

Restructuring related accelerated depreciation

800,000

1,400,000

2,100,000

6,800,000

Specialty Pharmaceuticals

Restructuring and related charges, net

(7,000,000)

(2,300,000)

(13,600,000)

(10,200,000)

Global Medical Imaging

Restructuring and related charges, net

(5,100,000)

(4,100,000)

(6,400,000)

(7,100,000)

Operating Segments

Net sales

^[1]

556,500,000

501,400,000

1,619,900,000

1,500,300,000

Operating income

108,300,000

100,200,000

316,300,000

289,000,000

Operating Segments | Specialty Pharmaceuticals

Net sales

308,600,000

254,700,000

913,200,000

746,300,000

Operating income

94,800,000

50,900,000

234,800,000

128,300,000

Operating Segments | Global Medical Imaging

Net sales

247,900,000

246,700,000

706,700,000

754,000,000

Operating income

13,500,000

49,300,000

81,500,000

160,700,000

Related Party

Net sales

^[2]

13,500,000

14,900,000

39,400,000

42,800,000

Corporate, Non-Segment

Corporate and allocated expenses

^[3]

(43,700,000)

(20,400,000)

(109,400,000)

(47,000,000)

Intangible asset amortization

(8,900,000)

(6,800,000)

(26,600,000)

(20,300,000)

Restructuring and related charges, net

^[4]

(12,100,000)

(6,400,000)

(20,000,000)

(17,300,000)

Separation costs

(44,200,000)

(7,200,000)

(70,600,000)

(17,400,000)

Intersegment Eliminations

Net sales

$ 0

[1]	Amounts represent sales to external customers. There were no intersegment sales.
[2]	Represents products that were sold to Covidien, which is discussed in note 11.
[3]	Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
[4]	Includes restructuring-related accelerated depreciation of $0.8 million and $1.4 million for the three months ended June 28, 2013 and June 29, 2012, respectively, and $2.1 million and $6.8 million for the nine months ended June 28, 2013 and June 29, 2012, respectively.

Subsequent Events (Details) - Equity Grants $ / shares in Millions	Jul. 01, 2013 Installment $ / shares shares
Subsequent Event [Line Items]
Options granted	406,169
Vesting \| Installment	2
Restricted Share Units
Subsequent Event [Line Items]
Rsu's granted	141,757
Stock Options and Restricted Stock Units
Subsequent Event [Line Items]
Fair value of grants \| $ / shares	$ 12.5